var title_f22_50_23328="Angle closure glaucoma";
var content_f22_50_23328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute angle closure glaucoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The conjunctival vessels are dilated, especially near the cornea (ciliary flush) and the cornea is slightly hazy (edematous).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trobe JD, Hackel RE. Field Guide to the Eyes. Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_50_23328=[""].join("\n");
var outline_f22_50_23328=null;
var title_f22_50_23329="Calculator: BODE Index for COPD survival prediction";
var content_f22_50_23329=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"BODE_form\" name=\"BODE_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: BODE Index for COPD survival prediction",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           FEV1 % Predicted After Bronchodialator",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"BODE_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &gt;=65% (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"BODE_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           50-64% (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"BODE_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           36-49% (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"BODE_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &lt;=35% (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           6 Minute Walk Distance",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"BODE_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &gt;=350 Meters (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"BODE_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           250-349 Meters (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"BODE_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           150-249 Meters (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"BODE_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &lt;=149 Meters (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           MMRC Dyspnea Scale (4 is worst)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"BODE_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           MMRC 0: Dyspneic on strenuous excercise (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"BODE_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           MMRC 1: Dyspneic on walking a slight hill (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"BODE_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           MMRC 2: Dyspneic on walking level ground; must stop occasionally due to breathlessness (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"BODE_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           MMRC 3: Must stop for breathlessness after walking 100 yards or after a few minutes (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"BODE_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           MMRC 4: Cannot leave house; breathless on dressing/undressing (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           Body Mass Index",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"BODE_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &gt;21 (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"BODE_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           &lt;=21 (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"       <tr>",
"        <td bgcolor=\"#eeeeee\" width=\"1%\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <span class=\"medCalcFontTitleBox\">",
"          Approximate 4 Year Survival Interpretation",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"        <tr id=\"rr1_1\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           0-2 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           80%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_2\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           3-4 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           67%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_3\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           5-6 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           57%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_4\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           7-10 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           18%",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       <b>",
"        BODE",
"       </b>",
"       stands for",
"       <b>",
"        B",
"       </b>",
"       ody mass index, airflow",
"       <b>",
"        O",
"       </b>",
"       bstruction,",
"       <b>",
"        D",
"       </b>",
"       yspnea and",
"       <b>",
"        E",
"       </b>",
"       xercise capacity [1].",
"      </li>",
"      <li>",
"       <b>",
"        MMRC",
"       </b>",
"       is the Modified Medical Reasearch Council Scale for dyspnea [2].",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Celli BR, Cote CG, Marin JM, et. al. The body-mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease.",
"        <i>",
"         N Engl J Med",
"        </i>",
"        . 2004 Mar 4;350(10):1005-12.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea.",
"        <i>",
"         Chest",
"        </i>",
"        . 1988 Mar;93(3):580-6.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"BODE_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_50_23329=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function BODE_fx() {",
"with(document.BODE_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1[0].checked){",
"Score = Score + 0;",
"}",
"if (cc1[1].checked){",
"Score = Score + 1;",
"}",
"if (cc1[2].checked){",
"Score = Score + 2;",
"}",
"if (cc1[3].checked){",
"Score = Score + 3;",
"}",
"if (cc2[0].checked){",
"Score = Score + 0;",
"}",
"if (cc2[1].checked){",
"Score = Score + 1;",
"}",
"if (cc2[2].checked){",
"Score = Score + 2;",
"}",
"if (cc2[3].checked){",
"Score = Score + 3;",
"}",
"if (cc3[0].checked){",
"Score = Score + 0;",
"}",
"if (cc3[1].checked){",
"Score = Score + 0;",
"}",
"if (cc3[2].checked){",
"Score = Score + 1;",
"}",
"if (cc3[3].checked){",
"Score = Score + 2;",
"}",
"if (cc3[4].checked){",
"Score = Score + 3;",
"}",
"if (cc4[0].checked){",
"Score = Score + 0;",
"}",
"if (cc4[1].checked){",
"Score = Score + 1;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"rrclr();",
"if ((Score >= 0) && (Score <= 2)){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if ((Score >= 3) && (Score <= 4)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"if ((Score >= 5) && (Score <= 6)){ document.getElementById('rr1_3').bgColor = '#cccccc';",
"}",
"if ((Score >= 7) && (Score <= 10)){ document.getElementById('rr1_4').bgColor = '#cccccc';",
"}",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f22_50_23329=null;
var title_f22_50_23330="Disorders androgen receptor";
var content_f22_50_23330=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F80831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F80831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Disorders of the androgen receptor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Complete androgen insensitivity is characterized by normal breast development and an overall female body habitus; axillary and pubic hair are markedly decreased or absent.",
"    <br>",
"     (B-D) Partial androgen insensitivity causes variable phenotypic manifestations, depending on the degree of functional impairment of the androgen receptor.",
"     <br>",
"      (B) Woman with mild virilization has a female habitus and female breasts but normal axillary and pubic hair and (variable) virilization of the clitoris and labioscrotal folds.",
"      <br>",
"       (C) The Reifenstein syndrome is characterized by a male body habitus, normal axillary and pubic hair but sparse facial and chest hair, hypospadias, and (in most) gynecomastia.",
"       <br>",
"        (D) Infertile male syndrome is manifested by a male body habitus, masculine facial and body hair, usually no gynecomastia, and normal male external genitalia.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         With permission from: Griffin JE, Wilson JD. Disorders of sexual differentiation, In: Campbell's Urology, Walsh PC, Retik AB, Stamey TA, Vaughan ED (Eds), Saunders, Philadelphia 1992. p.1528. (A) courtesy of Dr. Howard Jones (C), courtesy of Dr. Ronald Swerdloff, and (D) courtesy of Dr. James Aiman.",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_50_23330=[""].join("\n");
var outline_f22_50_23330=null;
var title_f22_50_23331="Open oophorectomy c";
var content_f22_50_23331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Open oophorectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The infundibulopelvic ligament (ovarian vessels) is then doubly ligated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_50_23331=[""].join("\n");
var outline_f22_50_23331=null;
var title_f22_50_23332="Benzyl alcohol: Patient drug information";
var content_f22_50_23332=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Benzyl alcohol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/61/20435?source=see_link\">",
"     see \"Benzyl alcohol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/10/12451?source=see_link\">",
"     see \"Benzyl alcohol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7897463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ulesfia&reg;;",
"     </li>",
"     <li>",
"      Zilactin&reg;-L [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat head lice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691791",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cold sores.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give this drug to a newborn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701610",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to benzyl alcohol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698317",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Scalp irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use carefully.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694436",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected part with a cotton swab.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696400",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Let dry for 15 seconds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694538",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid fire, flames, or smoking until dry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696424",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Lotion:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694807",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not wet hair before putting on lotion.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694638",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cover eyes and face with a towel.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694453",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Coat hair and scalp.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Work into hair and scalp gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695283",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not cover head while lotion is on hair.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695285",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Leave on for 10 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse fully.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use special nit comb or tweezers to get rid of dead nits (lice eggs) from hair.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash all bedding, towels, and recently worn clothes in hot water or have them dry cleaned.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat or open flame.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12187 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-655B890CD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_50_23332=[""].join("\n");
var outline_f22_50_23332=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897463\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026010\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026009\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026014\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026015\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026017\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026012\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026013\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026018\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026019\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/61/20435?source=related_link\">",
"      Benzyl alcohol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/10/12451?source=related_link\">",
"      Benzyl alcohol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_50_23333="Spinal cord infarction: Prognosis and treatment";
var content_f22_50_23333=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Spinal cord infarction: Prognosis and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/50/23333/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23333/contributors\">",
"     Michael Mullen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23333/contributors\">",
"     Michael L McGarvey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/50/23333/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23333/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/50/23333/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23333/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/50/23333/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 10, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord infarction is a rare disorder caused by a wide variety of pathologies. Patients typically present with acute paraparesis or quadriparesis depending on the level of the spinal cord involved. The severity can vary, and while many patients make some functional recovery, permanent and disabling neurologic deficits remain in most. Specific treatment options are unfortunately limited.",
"   </p>",
"   <p>",
"    This topic discusses the prognosis and acute treatment of spinal cord infarction. The causes, clinical symptoms, and diagnosis of spinal cord infarction are discussed separately. The management of chronic complications of spinal cord infarction is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40631?source=see_link\">",
"     \"Spinal cord infarction: Vascular anatomy and etiologies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30230?source=see_link\">",
"     \"Spinal cord infarction: Clinical presentation and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link\">",
"     \"Disorders affecting the spinal cord\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link\">",
"     \"Chronic complications of spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General medical care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the level and severity of spinal cord ischemia, patients are at risk for a number of systemic as well as neurologic complications in the first days and weeks. Some of these are potentially life-threatening and can exacerbate the neurologic injury. Early intervention can avoid and ameliorate many of these. Patients with moderate to severe deficits resulting from a high thoracic or cervical cord infarct should be admitted to an intensive care unit with close monitoring of vital signs and neurologic status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Cardiovascular complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurogenic shock refers to hypotension, usually with bradycardia, attributed to interruption of autonomic pathways in the spinal cord causing decreased vascular resistance. Patients with spinal cord infarction may also have hemodynamic instability related to the underlying etiology. An adequate blood pressure is believed to be critical in maintaining adequate perfusion to the ischemic, but not yet infarcted, spinal cord.",
"   </p>",
"   <p>",
"    Bradycardia can occur in severe, high cervical (C1 through C5) lesions and may require external pacing or administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Autonomic dysreflexia, a phenomenon characterized by episodic paroxysmal hypertension with headache, bradycardia, flushing, and sweating, is most often described after a traumatic spinal cord injury, but may be a potential concern after spinal cord infarction involving the cervical and upper thoracic cord as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link&amp;anchor=H4#H4\">",
"     \"Chronic complications of spinal cord injury\", section on 'Autonomic dysreflexia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Respiratory complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of pulmonary complications (respiratory failure, pulmonary edema, pneumonia, and pulmonary embolism) is highest with higher cervical lesions and is also common with thoracic lesions.",
"   </p>",
"   <p>",
"    Weakness of the diaphragm and chest wall muscles leads to impaired clearance of secretions, ineffective cough, atelectasis, and hypoventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23321?source=see_link\">",
"     \"Respiratory physiologic changes following spinal cord injury\"",
"    </a>",
"    .) Signs of impending respiratory failure, such as increased respiratory rate, declining forced vital capacity, rising pCO2, or falling pO2, indicate urgent intubation and ventilation with positive pressure support.",
"   </p>",
"   <p>",
"    With a goal of preventing atelectasis and pneumonia, chest physiotherapy should be instituted as soon as possible; patients may also need frequent suctioning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42439?source=see_link\">",
"     \"Respiratory complications of spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Venous thromboembolism and pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with significant paraparesis after spinal cord infarction should be treated to prevent deep venous thrombosis. Low-molecular-weight (LMW)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is considered the treatment of choice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pressure sores",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure sores are most common on the buttocks and heels and can develop quickly in immobilized patients. Such patients should be turned side to side (log-rolled) every two to three hours to avoid pressure sores. Special mattresses can also be used to ameliorate this complication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Urinary catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially, an indwelling urinary catheter should be placed to avoid bladder distension. Three or four days after injury, intermittent catheterization should be substituted, as this reduces the incidence of bladder infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link&amp;anchor=H9#H9\">",
"     \"Chronic complications of spinal cord injury\", section on 'Bladder dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Gastrointestinal stress ulceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with spinal cord infarction, particularly those that affect the cervical cord, are at high risk for stress ulceration, and should receive prophylaxis with proton pump inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=see_link\">",
"     \"Stress ulcer prophylaxis in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Temperature control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a cervical spinal cord injury may lack vasomotor control and cannot sweat below the lesion. Their temperature may vary with the environment and need to be maintained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Functional recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occupational and physiotherapy should be started as soon as possible. Psychological counseling should also be offered to patients and relatives as early as possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Specific treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;A specific protocol has been developed that appears to be effective in reversing or limiting the neurologic deficits from spinal cord ischemia after aortic surgery and thoracic endovascular aortic repair (TEVAR) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23333/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. This employs a combination of blood pressure support and reduction of spinal cord canal pressure with lumbar drains (",
"    <a class=\"graphic graphic_algorithm graphicRef51097 \" href=\"UTD.htm?30/43/31412\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean arterial pressure is increased in increments of 10mm Hg every five minutes (with volume and vasopressor agents) until symptoms resolve, bleeding complications ensue, or additional blood pressure augmentation would cause an unacceptably high risk of bleeding at the surgical bed.",
"     </li>",
"     <li>",
"      If a lumbar drain is in place, it should be opened and set to drain at 8 to 12mm Hg. If not in place, a lumbar drain should be placed if there is no response to blood pressure augmentation within 10 to 20 minutes.",
"     </li>",
"     <li>",
"      If there is no response to treatment, spinal imaging is performed to exclude epidural hematoma. MR imaging is preferred, but in cases where MRI is contraindicated or the patient is not stable enough to undergo MRI, CT is acceptable.",
"     </li>",
"     <li>",
"      Vasopressors are slowly weaned over the ensuing 24 to 48 hours, with close monitoring of neurologic function. After vasopressor support is weaned, the lumbar drain should be capped, and then removed 24 hours later if neurologic function remains stable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While this protocol has not been evaluated in a controlled study, the temporal association of the intervention with the observation of improvement provides evidence of its efficacy. Nonetheless the number of patients in whom this treatment has been reported is small (less than 15 patients).",
"   </p>",
"   <p>",
"    The use of this treatment protocol in spinal cord infarction due to other causes has not been studied. While these interventions could be considered, the benefit is questionable, particularly given the usually long delay from onset of symptoms to initiation of therapy in these settings.",
"   </p>",
"   <p>",
"    Thrombolytic therapy has been utilized with apparent success in only a few published case reports of spinal cord infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23333/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. A significant barrier to thrombolytic treatment in this situation is the initial diagnostic uncertainty that can delay diagnosis beyond the treatment window; this includes the need to exclude aortic dissection and vascular malformations, which are contraindications to thrombolytic agents. Thrombolytic therapy for spinal cord ischemia remains investigational at this time.",
"   </p>",
"   <p>",
"    Systemic corticosteroids have not been studied in acute ischemic injury to the spinal cord and are not recommended in acute ischemic stroke involving the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23333/abstract/7\">",
"     7",
"    </a>",
"    ]. We do not recommend the use of steroids to treat spinal cord infarction; however, in rare cases when it is not clear whether a patient has an ischemic versus a demyelinating spinal cord lesion, it may be reasonable to use corticosteroids pending a firm diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3061?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of acute exacerbations of multiple sclerosis in adults\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If an underlying etiology is found, it should be treated (ie, systemic vasculitis, aortic dissection, cardiogenic embolism), usually with a goal toward preventing further deterioration and secondary events rather than treating the primary injury. Vascular malformations of the spinal cord should be repaired if present. Repair of the malformation may prevent further neurologic decline, and in some instances lead to improved neurologic function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23333/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The use of antiplatelet treatment in patients with underlying vascular risk factors or comorbid vascular disease is recommended to prevent other secondary atherothrombotic events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with residual deficits after spinal cord infarction must often contend with a variety of other complications including bladder, bowel, and sexual dysfunction, spasticity, and chronic pain. The management of these conditions is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link\">",
"     \"Chronic complications of spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small case series have attempted to define the range of outcomes following spinal cord infarction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The case fatality rate varies depending on the case mix included in the series, but is often reported between 10 and 20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23333/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. Patients presenting in the setting of cardiac arrest and acute aortic rupture or dissection, and those with high cervical lesions are at greatest risk of dying.",
"     </li>",
"     <li>",
"      Among survivors, most make some improvement in functional deficits. Independent gait is achieved by 11 to 46 percent, while 20 to 57 percent remain wheelchair bound [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23333/abstract/10-15\">",
"       10-15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Poor prognostic factors for recovery include severe impairment at presentation, female sex, advanced age, and lack of improvement in the first 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23333/abstract/10,12-17\">",
"       10,12-17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with residual deficits after spinal cord infarction must often contend with a variety of other complications including bladder, bowel, and sexual dysfunction, spasticity, and chronic pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=see_link\">",
"     \"Chronic complications of spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord infarction is a rare disorder caused by a wide variety of pathologies. Patients typically present with acute paraparesis or quadriparesis, depending on the level of the spinal cord involved. The severity can vary and while many patients make some recovery, permanent and disabling neurologic deficits remain in most. Specific treatment options are limited.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depending on the level and severity of spinal cord ischemia, patients are at risk for potentially life-threatening complications. Patients with moderate to severe deficits resulting from a high thoracic or cervical cord infarct should be admitted to an intensive care unit with close monitoring of vital signs and neurologic status. Patients with significant paraparesis after spinal cord infarction should receive interventions to prevent deep venous thrombosis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General medical care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no therapies proven to reverse or limit ischemic spinal cord injury. A protocol for managing patients in the setting of thoracoabdominal aneurysm surgery is presented (",
"      <a class=\"graphic graphic_algorithm graphicRef51097 \" href=\"UTD.htm?30/43/31412\">",
"       algorithm 1",
"      </a>",
"      ), but this requires independent, prospective demonstration of its safety and efficacy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Specific treatments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Underlying causes should be treated in order to prevent secondary events. As an example, patients with atherosclerotic risk factors or underlying comorbid atherosclerotic vascular disease will benefit from antiplatelet therapy and management of atherosclerotic risk factors to prevent future stroke and myocardial infarction (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Specific treatments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mortality after spinal cord infarction is primarily influenced by the underlying etiology; however, patients with high cervical cord lesions are at risk of potentially life-threatening complications. Most survivors of spinal cord infarction make some functional improvements, but most have significant, residual neurologic deficits. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23333/abstract/1\">",
"      Cheung AT, Weiss SJ, McGarvey ML, et al. Interventions for reversing delayed-onset postoperative paraplegia after thoracic aortic reconstruction. Ann Thorac Surg 2002; 74:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23333/abstract/2\">",
"      Cheung AT, Pochettino A, McGarvey ML, et al. Strategies to manage paraplegia risk after endovascular stent repair of descending thoracic aortic aneurysms. Ann Thorac Surg 2005; 80:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23333/abstract/3\">",
"      McGarvey ML, Mullen MT, Woo EY, et al. The treatment of spinal cord ischemia following thoracic endovascular aortic repair. Neurocrit Care 2007; 6:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23333/abstract/4\">",
"      McGarvey ML, Cheung AT, Szeto W, Messe SR. Management of neurologic complications of thoracic aortic surgery. J Clin Neurophysiol 2007; 24:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23333/abstract/5\">",
"      Restrepo L, Guttin JF. Acute spinal cord ischemia during aortography treated with intravenous thrombolytic therapy. Tex Heart Inst J 2006; 33:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23333/abstract/6\">",
"      Baba H, Tomita K, Kawagishi T, Imura S. Anterior spinal artery syndrome. Int Orthop 1993; 17:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23333/abstract/7\">",
"      Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 2007; 115:e478.",
"     </a>",
"    </li>",
"    <li>",
"     Hurst, RW. Spinal vascular disorders. In: Magnetic Resonance Imaging of the Brain and Spine 2nd Edition, Atlas, SW (Ed), Lippincott, Philadelphia 2006. p.1387.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23333/abstract/9\">",
"      Van Dijk JM, TerBrugge KG, Willinsky RA, et al. Multidisciplinary management of spinal dural arteriovenous fistulas: clinical presentation and long-term follow-up in 49 patients. Stroke 2002; 33:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23333/abstract/10\">",
"      Cheshire WP, Santos CC, Massey EW, Howard JF Jr. Spinal cord infarction: etiology and outcome. Neurology 1996; 47:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23333/abstract/11\">",
"      Novy J, Carruzzo A, Maeder P, Bogousslavsky J. Spinal cord ischemia: clinical and imaging patterns, pathogenesis, and outcomes in 27 patients. Arch Neurol 2006; 63:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23333/abstract/12\">",
"      Masson C, Pruvo JP, Meder JF, et al. Spinal cord infarction: clinical and magnetic resonance imaging findings and short term outcome. J Neurol Neurosurg Psychiatry 2004; 75:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23333/abstract/13\">",
"      Nedeltchev K, Loher TJ, Stepper F, et al. Long-term outcome of acute spinal cord ischemia syndrome. Stroke 2004; 35:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23333/abstract/14\">",
"      Salvador de la Barrera S, Barca-Buyo A, Montoto-Marqu&eacute;s A, et al. Spinal cord infarction: prognosis and recovery in a series of 36 patients. Spinal Cord 2001; 39:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23333/abstract/15\">",
"      Iseli E, Cavigelli A, Dietz V, Curt A. Prognosis and recovery in ischaemic and traumatic spinal cord injury: clinical and electrophysiological evaluation. J Neurol Neurosurg Psychiatry 1999; 67:567.",
"     </a>",
"    </li>",
"    <li>",
"     Geldmacher DS, Bowen BC. Vascular Disease of the Nervous System. In: Neurology in Clinical Practice, 4th, Bradley WG, Daroff RB, Fenichel GM, Jankovic J (Eds), Butterworth Heinemann, Philadelphia 2004. p.1313.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23333/abstract/17\">",
"      Cheng MY, Lyu RK, Chang YJ, et al. Spinal cord infarction in Chinese patients. Clinical features, risk factors, imaging and prognosis. Cerebrovasc Dis 2008; 26:502.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1115 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-CC23815824-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_50_23333=[""].join("\n");
var outline_f22_50_23333=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General medical care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Cardiovascular complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Respiratory complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Venous thromboembolism and pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pressure sores",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Urinary catheterization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Gastrointestinal stress ulceration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Temperature control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Functional recovery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Specific treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1115\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1115|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?30/43/31412\" title=\"algorithm 1\">",
"      Treatment of spinal cord ischemia after thoracic aortic repair",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37642?source=related_link\">",
"      Chronic complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/28/42439?source=related_link\">",
"      Respiratory complications of spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23321?source=related_link\">",
"      Respiratory physiologic changes following spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30230?source=related_link\">",
"      Spinal cord infarction: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40631?source=related_link\">",
"      Spinal cord infarction: Vascular anatomy and etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3061?source=related_link\">",
"      Treatment of acute exacerbations of multiple sclerosis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_50_23334="Miconazole (topical): Drug information";
var content_f22_50_23334=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Miconazole (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/27/4533?source=see_link\">",
"    see \"Miconazole (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33844?source=see_link\">",
"    see \"Miconazole (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F196307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      3M&trade; Cavilon&trade; Antifungal [OTC];",
"     </li>",
"     <li>",
"      Aloe Vesta&reg; Antifungal [OTC];",
"     </li>",
"     <li>",
"      Baza&reg; Antifungal [OTC];",
"     </li>",
"     <li>",
"      Carrington&reg; Antifungal [OTC];",
"     </li>",
"     <li>",
"      Critic-Aid&reg; Clear AF [OTC];",
"     </li>",
"     <li>",
"      DermaFungal [OTC];",
"     </li>",
"     <li>",
"      Dermagran&reg; AF [OTC];",
"     </li>",
"     <li>",
"      DiabetAid&reg; Antifungal Foot Bath [OTC];",
"     </li>",
"     <li>",
"      Fungoid&reg; [OTC];",
"     </li>",
"     <li>",
"      Lotrimin AF&reg; [OTC];",
"     </li>",
"     <li>",
"      Micaderm&reg; [OTC];",
"     </li>",
"     <li>",
"      Micatin&reg; [OTC];",
"     </li>",
"     <li>",
"      Micro-Guard&reg; [OTC];",
"     </li>",
"     <li>",
"      Miranel AF&trade; [OTC];",
"     </li>",
"     <li>",
"      Mitrazol&reg; [OTC];",
"     </li>",
"     <li>",
"      Monistat&reg; 1 Day or Night [OTC];",
"     </li>",
"     <li>",
"      Monistat&reg; 1 [OTC];",
"     </li>",
"     <li>",
"      Monistat&reg; 3 [OTC];",
"     </li>",
"     <li>",
"      Monistat&reg; 7 [OTC];",
"     </li>",
"     <li>",
"      Neosporin&reg; AF [OTC];",
"     </li>",
"     <li>",
"      Podactin Cream [OTC];",
"     </li>",
"     <li>",
"      Secura&reg; Antifungal Extra Thick [OTC];",
"     </li>",
"     <li>",
"      Secura&reg; Antifungal Greaseless [OTC];",
"     </li>",
"     <li>",
"      Ting&reg; Spray Powder [OTC];",
"     </li>",
"     <li>",
"      Zeasorb&reg;-AF [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F196308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dermazole;",
"     </li>",
"     <li>",
"      Micatin&reg;;",
"     </li>",
"     <li>",
"      Micozole;",
"     </li>",
"     <li>",
"      Monistat&reg;;",
"     </li>",
"     <li>",
"      Monistat&reg; 3",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F196350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Topical;",
"     </li>",
"     <li>",
"      Antifungal Agent, Vaginal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F196312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tinea corporis:",
"     </b>",
"     Topical: Apply twice daily for 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tinea pedis:",
"     </b>",
"     Topical: Apply twice daily for 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Effervescent tablet:",
"     </i>",
"     Dissolve 1 tablet in ~1 gallon of water; soak feet for 15-30 minutes; pat dry",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tinea cruris:",
"     </b>",
"     Topical: Apply twice daily for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vulvovaginal candidiasis:",
"     </b>",
"     Vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cream, 2%:",
"     </i>",
"     Insert 1 applicatorful at bedtime for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cream, 4%:",
"     </i>",
"     Insert 1 applicatorful at bedtime for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Suppository, 100 mg:",
"     </i>",
"     Insert 1 suppository at bedtime for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Suppository, 200 mg:",
"     </i>",
"     Insert 1 suppository at bedtime for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Suppository, 1200 mg:",
"     </i>",
"     Insert 1 suppository (a one-time dose); may be used at bedtime or during the day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Many products are available as a combination pack, with a suppository for vaginal instillation and cream to relieve external symptoms. External cream may be used twice daily, as needed, for up to 7 days.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F196330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33844?source=see_link\">",
"      see \"Miconazole (topical): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Tinea corporis, tinea pedis, tinea cruris:",
"     </b>",
"     Topical:",
"     <b>",
"      Note:",
"     </b>",
"     Not for OTC use in children &lt;2 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Vulvovaginal candidiasis:",
"     </b>",
"     Vaginal: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F196313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F196288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, powder, topical, as nitrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lotrimin AF&reg;: 2% (133 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lotrimin AF&reg;: 2% (133 g) [deodorant formulation]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Micatin&reg;: 2% (90 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neosporin&reg; AF: 2% (85 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ting&reg; Spray Powder: 2% (128 g) [contains aloe, ethanol 10% w/w]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, topical, as nitrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Micatin&reg;: 2% (90 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Micatin&reg;: 2% (105 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neosporin&reg; AF: 2% (105 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Combination package, topical/vaginal, as nitrate: Cream, topical: 2% (9 g) and Suppository, vaginal: 200 mg (3s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monistat&reg; 3: Cream, topical: 2% (9 g) and Insert, vaginal: 200 mg (3s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monistat&reg; 7: Cream, topical: 2% (9 g) and Cream, vaginal: 2% (45 g), Cream, topical: 2% (9 g) and Cream, vaginal: 2% (7 x 5 g) [contains benzoic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monistat&reg; 3: Cream, topical: 2% (9 g) and Cream, vaginal: 4% (25 g), Cream, topical: 2% (9 g) and Cream, vaginal: 4% (3 x 5 g) [contains benzoic acid; vaginal cream 200 mg/applicator]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monistat&reg; 7: Cream, topical: 2% (9 g) and Suppository, vaginal: 100 mg (7s) [contains benzoic acid (in cream)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monistat&reg; 1: Cream, topical: 2% (9 g) and Insert, vaginal: 1200 mg (1) [contains benzoic acid (in cream), soya lecithin (in insert)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monistat&reg; 1 Day or Night: Cream, topical: 2% (9 g) and Insert, vaginal: 1200 mg (1) [contains benzoic acid (in cream), mineral oil (in insert), soya lecithin (in insert)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as nitrate: 2% (15 g, 30 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Baza&reg; Antifungal: 2% (4 g, 57 g, 142 g) [zinc oxide based formula]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carrington&reg; Antifungal: 2% (150 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Micaderm&reg;: 2% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Micatin&reg;: 2% (14 g) [contains benzoic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Micro-Guard&reg;: 2% (60 g [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miranel AF&trade;: 2% (28 g) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3M&trade; Cavilon&trade; Antifungal: 2% (56 g, 141 g) [contains castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neosporin&reg; AF: 2% (14 g, 15 g) [contains benzoic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Podactin Cream: 2% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Secura&reg; Antifungal Extra Thick: 2% (97.5 g) [contains zinc oxide]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Secura&reg; Antifungal Greaseless: 2% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, vaginal, as nitrate: 2% (45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monistat&reg; 7: 2% (45 g) [contains benzoic acid; 100 mg/applicator]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monistat&reg; 3: 4% (15 g, 25 g) [contains benzoic acid; 200 mg/applicator]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical, as nitrate [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lotrimin AF&reg;: 2% (150 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as nitrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aloe Vesta&reg; Antifungal: 2% (60 g, 150 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Critic-Aid&reg; Clear AF: 2% (57 g, 142 g, 300s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DermaFungal: 2% (120 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermagran&reg; AF: 2% (120 g) [zinc oxide based formula]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, topical, as nitrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lotrimin AF&reg;: 2% (90 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Micro-Guard&reg;: 2% (90 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mitrazol&reg;: 2% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zeasorb&reg;-AF: 2% (70 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, vaginal, as nitrate: 100 mg (7s); 200 mg (3s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet for solution, topical, as nitrate [effervescent]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DiabetAid&reg; Antifungal Foot Bath: 2% (10s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tincture, topical, as nitrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fungoid&reg;: 2% (7.39 mL, 30 mL) [contains isopropyl alcohol 30%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F196276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Cream (topical and vaginal), vaginal suppository",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F196291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of vulvovaginal candidiasis and a variety of skin and mucous membrane fungal infections",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F196356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Miconazole may be confused with metroNIDAZOLE, Micronase, Micronor&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lotrimin&reg; may be confused with Lotrisone&reg;, Otrivin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Micatin&reg; may be confused with Miacalcin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F196348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Allergic contact dermatitis, burning, maceration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vaginal: Abdominal cramps, burning, irritation, itching",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F196294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to miconazole or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F196280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: Discontinue if sensitivity or irritation occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Topical products are not for self-medication (OTC use) in children &lt;2 years of age; vaginal products are not for OTC use in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fungoid&reg; tincture: Patients with diabetes, circulatory problems, renal or hepatic dysfunction should contact healthcare provider prior to self-medication (OTC use).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Petrolatum-based: Vaginal products are petrolatum-based and may damage rubber or latex condoms or diaphragms; separate use by 3 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal products: Consult with healthcare provider prior to self-medication (OTC use) if experiencing vaginal itching/discomfort, lower abdominal pain, back or shoulder pain, chills, nausea, vomiting, foul-smelling discharge, if this is the first vaginal yeast infection, or if exposed to HIV. Contact healthcare provider if symptoms do not begin to improve after 3 days or last longer than 7 days. May damage condoms or diaphragms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical use only; avoid contact with eyes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F196346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F196284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Miconazole (Topical) may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F196303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St John's wort may decrease miconazole levels.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13825032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following vaginal administration, small amounts are absorbed systemically. Adverse fetal events have not been observed and vaginal products may be considered for the treatment of vulvovaginal candidiasis in pregnant women (CDC, 2010; Czeizel, 2004; Stevens, 2002).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F196315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F196296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol",
"     </b>",
"     (Desenex Spray External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (133 g): $5.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol powder",
"     </b>",
"     (Cruex Prescription Strength External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (85 g): $5.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol powder",
"     </b>",
"     (Desenex Jock Itch External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (113 g): $5.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol powder",
"     </b>",
"     (Miconazole Nitrate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (131 g): $3.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Micatin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (14 g): $5.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Miconazole Nitrate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (28 g): $3.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Miconazole Nitrate Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (45 g): $11.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Micro Guard External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (57 g): $7.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Monistat 3 Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (5 g): $4.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Monistat 7 Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (45 g): $9.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Secura Antifungal External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (57 g): $11.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Secura Antifungal Extra Thick External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (92 g): $14.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Fungoid Tincture External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (1): $35.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Monistat 1 Combo Pack Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1200 mg 2% (1): $16.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Monistat 3 Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg 2% (9g) (1): $14.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Monistat 7 Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg 2% (1): $12.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Vagistat-3 Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg 2% (9g) (1): $9.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Zeasorb-AF External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (56 g): $10.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Aloe Vesta Antifungal External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (56 g): $6.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Critic-Aid Clear AF External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (57 g): $8.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (DermaFungal External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (113 g): $10.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Dermagran AF External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (113 g): $9.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Tetterine External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (30 g): $3.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Desenex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (45 g): $3.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Lotrimin AF External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (90 g): $5.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Micro Guard External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (85 g): $8.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Mitrazol External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (30 g): $11.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Zeasorb-AF External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (71 g): $5.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Azolen Tincture External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (29.57 mL): $17.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fungoid Tincture External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (29.57 mL): $19.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Miranel AF External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (28 g): $18.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Miconazole Nitrate Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (7): $6.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Monistat 7 Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (7): $12.08",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F196297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Albistat (LU);",
"     </li>",
"     <li>",
"      Aloid (MX);",
"     </li>",
"     <li>",
"      Becarin (MY);",
"     </li>",
"     <li>",
"      Brentan (DK);",
"     </li>",
"     <li>",
"      Candiplas (SG);",
"     </li>",
"     <li>",
"      Candizol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Candizol oral (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Dacta Oral Gel (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Dacta Topical Gel (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Dafrin (TW);",
"     </li>",
"     <li>",
"      Daktar (LU, NO, SE);",
"     </li>",
"     <li>",
"      Daktarin (AR, AT, AU, BB, BD, BE, BF, BG, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CZ, EC, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HR, ID, IE, IL, IT, JM, JP, KE, KP, LR, LU, MA, ML, MR, MU, MW, MX, NE, NG, NL, NZ, PE, PH, PK, PL, PT, PY, RU, SC, SD, SG, SL, SN, SR, TH, TN, TT, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      De-Ol (PH);",
"     </li>",
"     <li>",
"      Dermon (HK, MY);",
"     </li>",
"     <li>",
"      Dermonistat (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Fungtopic (PH);",
"     </li>",
"     <li>",
"      Gyno-Daktarin (AE, BD, BG, BH, CY, CZ, EE, EG, FI, HR, IQ, IR, JO, JP, KP, KW, LB, LU, LY, MX, OM, QA, RU, SA, SY, YE);",
"     </li>",
"     <li>",
"      Hipo Femme (MX);",
"     </li>",
"     <li>",
"      Leuko Fungex (NZ);",
"     </li>",
"     <li>",
"      Lotrimin AF (MX);",
"     </li>",
"     <li>",
"      Miconazol (MX);",
"     </li>",
"     <li>",
"      Miconol (AR);",
"     </li>",
"     <li>",
"      Micreme (NZ);",
"     </li>",
"     <li>",
"      Moladerm (ID);",
"     </li>",
"     <li>",
"      Mycoheal Cream (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Mycoheal Oral Gel (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Mykoderm (DE);",
"     </li>",
"     <li>",
"      Nacomic (MX);",
"     </li>",
"     <li>",
"      Neomicol (CR, DO, GT, HN, MX, NI, PA, SV);",
"     </li>",
"     <li>",
"      Noxrakin (TH);",
"     </li>",
"     <li>",
"      Pitrion (IL);",
"     </li>",
"     <li>",
"      Resolve Jock Itch (AU);",
"     </li>",
"     <li>",
"      Resolve Solution (AU, SG);",
"     </li>",
"     <li>",
"      Resolve Tinea (AU, MY, SG);",
"     </li>",
"     <li>",
"      Rojazol (HR);",
"     </li>",
"     <li>",
"      Skindure (TH);",
"     </li>",
"     <li>",
"      Zarin (MY);",
"     </li>",
"     <li>",
"      Zole (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F196279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits biosynthesis of ergosterol, damaging the fungal cell wall membrane, which increases permeability causing leaking of nutrients",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F196293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: Negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces; urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/50/23334/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Czeizel AE, Kazy Z, and Puh&oacute; E, \"Population-Based Case-Control Teratologic Study of Topical Miconazole,\"",
"      <i>",
"       Congenit Anom (Kyoto)",
"      </i>",
"      , 2004, 44(1):41-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/50/23334/abstract-text/15008899/pubmed\" id=\"15008899\" target=\"_blank\">",
"        15008899",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pappas PG, Kauffman CA, Andes D, et al, &ldquo;Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Disease Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(5):503-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/50/23334/abstract-text/19191635/pubmed\" id=\"19191635\" target=\"_blank\">",
"        19191635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens RE, Konsil J, Verrill SS, et al, \"Bioavailability Study of a 1200 mg Miconazole Nitrate Vaginal Ovule in Healthy Female Adults,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2002, 42(1):52-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/50/23334/abstract-text/11808824/pubmed\" id=\"11808824\" target=\"_blank\">",
"        11808824",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9649 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-EF161DC620-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_50_23334=[""].join("\n");
var outline_f22_50_23334=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196307\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196308\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196350\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196312\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196330\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196313\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196288\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196276\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196291\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196356\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196348\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196294\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196280\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196346\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196284\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196303\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825032\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196315\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196296\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196297\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196279\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196293\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9649\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9649|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/27/4533?source=related_link\">",
"      Miconazole (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33844?source=related_link\">",
"      Miconazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_50_23335="Pathophysiology of stunned or hibernating myocardium";
var content_f22_50_23335=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of stunned or hibernating myocardium",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/50/23335/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23335/contributors\">",
"     David M Shavelle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/50/23335/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23335/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23335/contributors\">",
"     Jeroen J Bax, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/50/23335/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23335/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/50/23335/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular (LV) dysfunction, an important consequence of coronary artery disease, can result from myocardial ischemia or myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In some patients, transient ischemia can lead to a period of persistent dysfunction after the restoration of flow while in others persistent, asymptomatic ischemia produces LV dysfunction that can mimic nonischemic causes of heart failure. The former phenomenon is referred to as myocardial stunning and the latter as hibernating myocardium.",
"   </p>",
"   <p>",
"    The definitions and pathophysiology of myocardial stunning and hibernation will be reviewed here. The approach to diagnosis and therapy of hibernation, the clinical syndromes associated with stunned or hibernating myocardium, and the role of nuclear imaging and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography to assess myocardial viability are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=see_link\">",
"     \"Evaluation of hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8759?source=see_link\">",
"     \"Clinical syndromes of stunned or hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=see_link\">",
"     \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=see_link\">",
"     \"Dobutamine stress echocardiography in the evaluation of hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hibernating myocardium must be distinguished from the stunned myocardium and from transient LV dysfunction that is a result of ischemia induced by stress (eg, exercise,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    ). However, hibernating myocardium can coexist with both conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Stunned myocardium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stunned myocardium was the term initially used to describe a condition demonstrated in the laboratory in which total coronary artery occlusion lasting only 5 to 15 minutes (a period not associated with cell death) produced an abnormality in regional LV wall motion that persisted for hours or days following reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Thus, the key elements of the stunned myocardium are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Short-term, total or near total reduction of coronary blood flow",
"     </li>",
"     <li>",
"      Reestablishment of coronary bl",
"1ff8",
"ood flow",
"     </li>",
"     <li>",
"      Subsequent LV dysfunction of limited duration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the clinical setting, stunned myocardium may be superimposed on ischemia (including variant angina and during and after coronary revascularization), hibernation, or infarction when blood flow is reestablished [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hibernating myocardium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hibernating myocardium is a state of persistently impaired myocardial and LV function at rest due to chronically reduced coronary blood flow that can be partially or completely restored to normal either by improving blood flow or by reducing oxygen demand [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/1,9-15\">",
"     1,9-15",
"    </a>",
"    ]. The reduction in resting coronary blood flow in hibernating segments and the improvement following percutaneous coronary intervention have been directly demonstrated by cardiovascular magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Positron emission tomography (PET) has shown that regions with abnormal wall motion may still be metabolically active; these are the regions that can improve after revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/17\">",
"     17",
"    </a>",
"    ]. Such regions are likely to be hypokinetic rather than akinetic or dyskinetic. In an autopsy series, 52 percent of myocardial segments that were hypokinetic had normal myocardium when examined histologically compared to only 7 percent of akinetic or dyskinetic segments [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myocardial hibernation may be acute, subacute, or chronic, and can be superimposed upon stable or unstable angina and myocardial infarction (",
"    <a class=\"graphic graphic_figure graphicRef55431 \" href=\"UTD.htm?30/36/31309\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/1\">",
"     1",
"    </a>",
"    ]. Hibernating myocardium can be completely, or almost completely, restored to normal with therapy if the myocardial oxygen",
"    <span class=\"nowrap\">",
"     supply/demand",
"    </span>",
"    relationship is favorably altered, either by improving blood flow",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by reducing demand. On the other hand, if the hibernating myocardium is not treated in a timely manner, it may be associated with progressive cellular damage, recurrent myocardial ischemia, myocardial infarction, heart failure, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential impact of hibernating myocardium was illustrated in a study of 112 cardiac transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/20\">",
"     20",
"    </a>",
"    ]. Severe coronary disease was found in all patients with a pretransplant diagnosis of ischemic cardiomyopathy (57 percent of the total population); it was also present in nine of 38 patients with a pretransplant diagnosis of idiopathic dilated cardiomyopathy and in three of four with presumptive alcoholic cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prerequisite for stunning and hibernation is a reduction in myocardial blood flow (",
"    <a class=\"graphic graphic_figure graphicRef62157 \" href=\"UTD.htm?27/21/27997\">",
"     figure 2",
"    </a>",
"    ). If contributions from collaterals, plaque morphology, and abnormal microvasculature are ignored, then a coronary stenosis of up to approximately 40 percent will not alter maximum blood flow, and coronary flow reserve will remain normal. Between 40 and 80 percent stenosis, resting myocardial blood flow will be normal, but maximum blood flow will be diminished; in this setting, episodes of increased oxygen demand may result in stunning. A stenosis greater than 80 percent is likely to be associated with a reduction in resting blood flow and could result in reduced contraction through perfusion-contraction matching. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Myocardial adaption to ischemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is conceivable that, in the presence of a high grade stenosis, flow which was normal at rest may at times be reduced, and vice versa. If this is viewed in terms of perfusion-contraction matching, then myocardium which at one time point is by definition \"stunned\" may at another point in time be hypoperfused and therefore hibernating without any alteration in LV systolic contraction or cardiac output (",
"    <a class=\"graphic graphic_figure graphicRef62157 \" href=\"UTD.htm?27/21/27997\">",
"     figure 2",
"    </a>",
"    ). There may also be transmural variations in myocardial blood flow. Thus, within one hypocontractile segment, it is possible that areas of dysfunction secondary to stunning and hypoperfusion may coexist and then interchange at another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Relation between hibernation and stunning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding observations suggest that the difference between hibernation and stunning may be one of degree: in hibernation, resting blood flow is low, whereas in stunning resting flow is normal but maximal blood flow is reduced (",
"    <a class=\"graphic graphic_figure graphicRef55431 \" href=\"UTD.htm?30/36/31309\">",
"     figure 1",
"    </a>",
"    ). There may, however, be considerable overlap between these phenomena (",
"    <a class=\"graphic graphic_table graphicRef71436 \" href=\"UTD.htm?24/39/25211\">",
"     table 1",
"    </a>",
"    ). As an example, absolute myocardial blood flow may be normal or near normal in some hibernating segments [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. However, coronary flow reserve, ie, the ratio of maximum to basal coronary flow, may be reduced within these segments, leading to the hypothesis that hibernation may result from repetitive stunning, secondary to repeated episodes of ischemia or from chronic stunning.",
"   </p>",
"   <p>",
"    A number of studies provide support for the transition from repetitive stunning to hibernation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a canine study, multiple coronary artery obstructions resulted in collateral dependent, noninfarcted, and reversibly dysfunctional myocardium, representing stunning; this early phase of episodic dysfunction was followed by persistent dysfunction in the presence of normal resting blood flow and was characterized at a later stage by persistent dysfunction and subendocardial hypoperfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A temporal transition from chronic stunning to hibernation was seen in an animal study in which chronic stunning, with normal resting perfusion, was produced by a gradual increase in stenosis severity [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/25\">",
"       25",
"      </a>",
"      ]. As coronary flow reserve, demonstrated by adenosine, decreased over two months, there was an increase in the uptake of the glucose analog, fluorine-18 labeled deoxyglucose (FDG), characteristic of hibernating myocardium. These data suggest that both coronary flow reserve and the length of time during which the heart is subjected to reversible ischemia are determinants of increased FDG uptake and the transition to hibernating myocardium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Myocardial stunning and hibernation share other features that suggest that they are not completely separate phenomena (",
"1ff8",
"    <a class=\"graphic graphic_table graphicRef71436 \" href=\"UTD.htm?24/39/25211\">",
"     table 1",
"    </a>",
"    ). In both, there is a resting wall motion abnormality occurring as a result of coronary disease, which improves following the restoration of flow. In addition, contractility will respond to inotropes in both phenomena, which provides the rationale for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography in patients with suspected hibernating myocardium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=see_link\">",
"     \"Dobutamine stress echocardiography in the evaluation of hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both phenomena are also associated with a switch from free fatty acids to glucose as the preferred substrate, which provides the rationale for the use of radionuclide myocardial perfusion imaging with FDG in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=see_link\">",
"     \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Myocardial adaption to ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a relation between myocardial blood flow and systolic function, the so-called \"flow function\" relation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. As blood flow is reduced, there is a corresponding reduction in contractile performance (\"perfusion-contraction matching\"). There may no ischemic symptoms or necrosis when this occurs slowly since blood flow and function are once again in equilibrium [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the hibernating response of the heart, namely, a reduction of function to cope with a reduced myocardial blood flow, could be considered an act of self preservation (little blood, little work) and the heart could be considered to be a \"smart heart.\" If, however, myocardial oxygen",
"    <span class=\"nowrap\">",
"     supply/demand",
"    </span>",
"    balance is subsequently altered unfavorably, then symptoms and signs of ischemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    necrosis can occur. As an example, intermittent brief episodes of ischemia can have a cumulative effect, leading to myocardial necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If blood flow remains low, the myocardium may be able to reduce its metabolic requirements still further by undergoing a more chronic form of adaptation involving alterations in the morphology and protein content of the myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/22,30-33\">",
"     22,30-33",
"    </a>",
"    ]. These changes, which have been well documented and can be quite profound, are viewed by some as an adaptation to substrate deprivation and by others as degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/30,32-34\">",
"     30,32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dedifferentiation or embryonic regression is an active adaptive process to reduced flow, supporting the \"smart heart\" hypothesis.",
"     </li>",
"     <li>",
"      Supporting the forced degeneration hypothesis are the observations that some myocytes show nucleolar condensations suggestive of apoptosis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/35\">",
"       35",
"      </a>",
"      ] and that cardiac myocyte apoptosis can be triggered by ischemia (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Myocardial changes associated with hibernation'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whatever the cause, structural remodeling would be necessary to restore contractility. As a result, chronically impaired but viable myocardium may take weeks or months to recover once flow is restored [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not demonstrated in all studies, transient disturbances in contraction have been documented following exercise in patients with coronary artery disease, particularly when multivessel disease is present [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. It seems likely that transient wall motion abnormalities will occur in areas of myocardium subtended by a coronary stenosis that have reduced coronary flow reserve even thought the stenosis is not severe enough to diminish resting myocardial blood flow. In such patients, another period of ischemia may occur before the myocardium has had time to recover fully from the first episodes. Thus, repeated episodes of ischemia may result in an apparent chronic reduction in left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ischemic preconditioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another phenomenon closely associated with stunning is ischemic preconditioning. This was originally defined as a brief period of ischemia protecting the myocardium from a subsequent more prolonged period of ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/39\">",
"     39",
"    </a>",
"    ]. Implicit in this definition is a defined period of reperfusion between the triggering (preconditioning) ischemia and the subsequent prolonged period of ischemia. However, the phenomenon can also be triggered if the onset of ischemia is gradual rather than sudden, so-called intra-ischemic preconditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It appears that classic preconditioning resembles repetitive stunning, while intra-ischemic preconditioning resembles flow-function matching in hibernation. It is therefore possible that one of the mechanisms by which clinically hibernating myocardium survives the disturbance in myocardial blood flow is by being preconditioned. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9673?source=see_link\">",
"     \"Definition and pathogenesis of ischemic preconditioning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=see_link\">",
"     \"Clinical implications of ischemic preconditioning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Coronary autoregulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In humans, there are extensive autoregulatory processes that maintain coronary blood flow despite changes in mean coronary pressure. Over a wide range of coronary pressures, coronary blood flow remains normal, largely through variations in arterial tone. As coronary pressure falls, for example, vasodilatation occurs, maintaining flow. Once maximum vasodilatation is present, any further reduction in coronary pressure will result in a precipitous reduction in flow. This relation between pressure and flow is influenced by numerous factors, such as sympathetic tone, hypertrophy, tachycardia, left ventricular end-diastolic pressure, viscosity, infarction, medial smooth muscle tone, and cyclical platelet aggregation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Myocardial changes associated with hibernation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in animals and humans suggest that, during long-term myocardial hypoperfusion, there is ongoing myocyte death through apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/35,41,42\">",
"     35,41,42",
"    </a>",
"    ]. There is also structural degeneration characterized by reduced protein and mRNA expression, disorganization of the contractile and cytoskeletal pro",
"1ff8",
"teins, an increased amount of extracellular matrix proteins and reparative fibrosis, and a progressive reduction and disruption of connexin43 gap junctions which may contribute to the electromechanical dysfunction and to arrhythmogenicity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These degenerative changes and deterioration in myocardial function are time-dependent. In a study of 32 patients, those with subacute hibernation (&lt;50 days from onset of new or worsening symptoms) had a higher preoperative left ventricular ejection fraction and better preserved wall motion than patients who had intermediate (&gt;50 days) or chronic (&gt;6 months) ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/44\">",
"     44",
"    </a>",
"    ]. Structural degeneration, based upon biopsy samples obtained at the time of bypass surgery, correlated with the duration of ischemia, while recovery of function after revascularization correlated inversely with the duration of ischemia, being most pronounced in those with subacute hibernation.",
"   </p>",
"   <p>",
"    There are inconclusive data from animal models and human studies regarding the underlying mechanisms of reversible chronic left ventricular dysfunction. Animal models have demonstrated that significant regional and global dysfunction can exist without extensive cell necrosis in the presence of a coronary stenosis as long as there is preserved resting perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. How this occurs is not well understood but the following factors may contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced myocardial high energy phosphates",
"     </li>",
"     <li>",
"      Impaired calcium handling by the sarcoplasmic reticulum",
"     </li>",
"     <li>",
"      Diminished sensitivity of myofibrils to calcium",
"     </li>",
"     <li>",
"      A shift from aerobic or oxidative metabolism of free fatty acids to anaerobic metabolism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The underperfused myocardium retains its responsiveness to an inotropic challenge even though there is no change in regional blood flow; this observation suggests that the reduction in contractility is not entirely due to a decrease in energy stores [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/11,50\">",
"     11,50",
"    </a>",
"    ]. As mentioned above, it is still uncertain if the chronic contractile dysfunction is due to persistent ischemia (representing true hibernation) or to repetitive episodes of ischemia and reperfusion (representing myocardial stunning) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Altered adrenergic density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alteration in the density of alpha and beta adrenergic receptors have been observed in various pathologic states associated with myocardial dysfunction, particularly heart failure. Alterations in adrenergic receptor density may also play a role in the depression of myocardial function and preserved contractile reserve seen in hibernation. In one histologic study of myocardial biopsies from patients with ischemic left ventricular dysfunction who underwent bypass surgery, segments that were dysfunctional but viable, as determined by preoperative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography and radionuclide myocardial perfusion imaging, showed an increase in alpha receptor density, a decrease in beta receptor density, and an increase in the ratio of alpha to beta receptor density compared to normal segments [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23335/abstract/51\">",
"     51",
"    </a>",
"    ]. Worsening of resting function, inotropic reserve, and recovery of function were all associated with a graded increase in alpha receptor density and a decrease in beta receptor density.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116884992\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hibernating myocardium is a state of persistently impaired left ventricular myocardial function at rest due to chronically reduced coronary blood flow that can be partially or completely restored to normal either by improving blood flow or by reducing oxygen demand. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hibernating myocardium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stunned myocardium was the term initially used to describe a condition demonstrated in the laboratory in which total coronary artery occlusion lasting only 5 to 15 minutes (a period not associated with cell death) produced an abnormality in regional left ventricular wall motion that persisted for hours or days following reperfusion. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Stunned myocardium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A prerequisite for stunning and hibernation is a reduction in myocardial blood flow. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/1\">",
"      Rahimtoola SH. The hibernating myocardium in ischaemia and congestive heart failure. Eur Heart J 1993; 14 Suppl A:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/2\">",
"      Opie LH. The ever expanding spectrum of ischemic left ventricular dysfunction. Cardiovasc Drugs Ther 1994; 8 Suppl 2:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/3\">",
"      Heyndrickx GR, Millard RW, McRitchie RJ, et al. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest 1975; 56:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/4\">",
"      Heyndrickx GR, Baig H, Nellens P, et al. Depression of regional blood flow and wall thickening after brief coronary occlusions. Am J Physiol 1978; 234:H653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/5\">",
"      Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 1982; 66:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/6\">",
"      Marban E. Myocardial stunning and hibernation. The physiology behind the colloquialisms. Circulation 1991; 83:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/7\">",
"      Bolli R. Myocardial 'stunning' in man. Circulation 1992; 86:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/8\">",
"      Gerber BL, Wijns W, Vanoverschelde JL, et al. Myocardial perfusion and oxygen consumption in reperfused noninfarcted dysfunctional myocardium after unstable angina: direct evidence for myocardial stunning in humans. J Am Coll Cardiol 1999; 34:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/9\">",
"      Braunwald E, Rutherford JD. Reversible ischemic left ventricular dysfunction: evidence for the \"hibernating myocardium\". J Am Coll Cardiol 1986; 8:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/10\">",
"      Rahimtoola SH. The hibernating myocardium. Am Heart J 1989; 117:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./pathophysiology-of-stunned-or-hiberna",
"1ff8",
"ting-myocardium/abstract/11\">",
"      Schulz R, Guth BD, Pieper K, et al. Recruitment of an inotropic reserve in moderately ischemic myocardium at the expense of metabolic recovery. A model of short-term hibernation. Circ Res 1992; 70:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/12\">",
"      Bolukoglu H, Liedtke AJ, Nellis SH, et al. An animal model of chronic coronary stenosis resulting in hibernating myocardium. Am J Physiol 1992; 263:H20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/13\">",
"      Schulz R, Rose J, Martin C, et al. Development of short-term myocardial hibernation. Its limitation by the severity of ischemia and inotropic stimulation. Circulation 1993; 88:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/14\">",
"      Downing SE, Chen V. Acute hibernation and reperfusion of the ischemic heart. Circulation 1992; 85:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/15\">",
"      Bristow JD, Arai AE, Anselone CG, Pantely GA. Response to myocardial ischemia as a regulated process. Circulation 1991; 84:2580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/16\">",
"      Selvanayagam JB, Jerosch-Herold M, Porto I, et al. Resting myocardial blood flow is impaired in hibernating myocardium: a magnetic resonance study of quantitative perfusion assessment. Circulation 2005; 112:3289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/17\">",
"      Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/18\">",
"      Cabin HS, Clubb KS, Vita N, Zaret BL. Regional dysfunction by equilibrium radionuclide angiocardiography: a clinicopathologic study evaluating the relation of degree of dysfunction to the presence and extent of myocardial infarction. J Am Coll Cardiol 1987; 10:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/19\">",
"      Knight C, Fox K. The vicious circle of ischemic left ventricular dysfunction. Am J Cardiol 1995; 75:10E.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/20\">",
"      Bortman G, Sellanes M, Odell DS, et al. Discrepancy between pre- and post-transplant diagnosis of end-stage dilated cardiomyopathy. Am J Cardiol 1994; 74:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/21\">",
"      Marinho NV, Keogh BE, Costa DC, et al. Pathophysiology of chronic left ventricular dysfunction. New insights from the measurement of absolute myocardial blood flow and glucose utilization. Circulation 1996; 93:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/22\">",
"      Vanoverschelde JL, Wijns W, Depr&eacute; C, et al. Mechanisms of chronic regional postischemic dysfunction in humans. New insights from the study of noninfarcted collateral-dependent myocardium. Circulation 1993; 87:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/23\">",
"      Vanoverschelde JL, Wijns W, Borgers M, et al. Chronic myocardial hibernation in humans. From bedside to bench. Circulation 1997; 95:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/24\">",
"      Shivalkar B, Flameng W, Szilard M, et al. Repeated stunning precedes myocardial hibernation in progressive multiple coronary artery obstruction. J Am Coll Cardiol 1999; 34:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/25\">",
"      Fallavollita JA, Canty JM Jr. Differential 18F-2-deoxyglucose uptake in viable dysfunctional myocardium with normal resting perfusion: evidence for chronic stunning in pigs. Circulation 1999; 99:2798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/26\">",
"      Kim SJ, Peppas A, Hong SK, et al. Persistent stunning induces myocardial hibernation and protection: flow/function and metabolic mechanisms. Circ Res 2003; 92:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/27\">",
"      Ross J Jr. Myocardial perfusion-contraction matching. Implications for coronary heart disease and hibernation. Circulation 1991; 83:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/28\">",
"      Gallagher KP. Myocardial hibernation in terms of the flow-function relationship. Basic Res Cardiol 1995; 90:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/29\">",
"      Geft IL, Fishbein MC, Ninomiya K, et al. Intermittent brief periods of ischemia have a cumulative effect and may cause myocardial necrosis. Circulation 1982; 66:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/30\">",
"      Ausma J, Cleutjens J, Thon&eacute; F, et al. Chronic hibernating myocardium: interstitial changes. Mol Cell Biochem 1995; 147:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/31\">",
"      Ausma J, F&uuml;rst D, Thon&eacute; F, et al. Molecular changes of titin in left ventricular dysfunction as a result of chronic hibernation. J Mol Cell Cardiol 1995; 27:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/32\">",
"      Borgers, M, Thone, F, Wouters, L, et al. Structural correlates of regional myocardial dysfunction in patients with critical coronary artery stenosis: Chronic hibernation? Cardiovasc Pathol 1993; 2:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/33\">",
"      Depr&eacute; C, Vanoverschelde JL, Melin JA, et al. Structural and metabolic correlates of the reversibility of chronic left ventricular ischemic dysfunction in humans. Am J Physiol 1995; 268:H1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/34\">",
"      Ausma, J, Sehaart, G, Thone, F, et al. Chronic ischemic viable myocardium in man: Aspects of dedifferentiation. Cardiovasc Pathol 1995; 4:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/35\">",
"      Schwarz ER, Schaper J, vom Dahl J, et al. Myocyte degeneration and cell death in hibernating human myocardium. J Am Coll Cardiol 1996; 27:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/36\">",
"      Scognamiglio R, Ponchia A, Fasoli G, et al. Exercise-induced left ventricular dysfunction in coronary heart disease. A model for studying the stunned myocardium in man. Eur Heart J 1991; 12 Suppl G:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/37\">",
"      Kloner RA, Allen J, Cox TA, et al. Stunned left ventricular myocardium after exercise treadmill testing in coronary artery disease. Am J Cardiol 1991; 68:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/38\">",
"      Homans DC, Laxson DD, Sublett E, et al. Cumulative deterioration of myocardial function after repeated episodes of exercise-induced ischemia. Am J Physiol 1989; 256:H14",
"1ff8",
"62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/39\">",
"      Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/40\">",
"      Ito BR. Gradual onset of myocardial ischemia results in reduced myocardial infarction. Association with reduced contractile function and metabolic downregulation. Circulation 1995; 91:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/41\">",
"      Chen C, Ma L, Linfert DR, et al. Myocardial cell death and apoptosis in hibernating myocardium. J Am Coll Cardiol 1997; 30:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/42\">",
"      Els&auml;sser A, Schlepper M, Kl&ouml;vekorn WP, et al. Hibernating myocardium: an incomplete adaptation to ischemia. Circulation 1997; 96:2920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/43\">",
"      Kaprielian RR, Gunning M, Dupont E, et al. Downregulation of immunodetectable connexin43 and decreased gap junction size in the pathogenesis of chronic hibernation in the human left ventricle. Circulation 1998; 97:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/44\">",
"      Schwarz ER, Schoendube FA, Kostin S, et al. Prolonged myocardial hibernation exacerbates cardiomyocyte degeneration and impairs recovery of function after revascularization. J Am Coll Cardiol 1998; 31:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/45\">",
"      Anversa P, Zhang X, Li P, Capasso JM. Chronic coronary artery constriction leads to moderate myocyte loss and left ventricular dysfunction and failure in rats. J Clin Invest 1992; 89:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/46\">",
"      Capasso JM, Jeanty MW, Palackal T, et al. Ventricular remodeling induced by acute nonocclusive constriction of coronary artery in rats. Am J Physiol 1989; 257:H1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/47\">",
"      Schulz R, Heusch G. Characterization of hibernating and stunned myocardium. Eur Heart J 1995; 16 Suppl J:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/48\">",
"      Heusch G, Rose J, Skyschally A, et al. Calcium responsiveness in regional myocardial short-term hibernation and stunning in the in situ porcine heart. Inotropic responses to postextrasystolic potentiation and intracoronary calcium. Circulation 1996; 93:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/49\">",
"      Shimonagata T, Nanto S, Kusuoka H, et al. Metabolic changes in hibernating myocardium after percutaneous transluminal coronary angioplasty and the relation between recovery in left ventricular function and free fatty acid metabolism. Am J Cardiol 1998; 82:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/50\">",
"      Schulz R, Rose J, Post H, Heusch G. Regional short-term myocardial hibernation in swine does not involve endogenous adenosine or KATP channels. Am J Physiol 1995; 268:H2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23335/abstract/51\">",
"      Shan K, Bick RJ, Poindexter BJ, et al. Altered adrenergic receptor density in myocardial hibernation in humans: A possible mechanism of depressed myocardial function. Circulation 2000; 102:2599.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1516 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.28.111.102-322217C268-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_50_23335=[""].join("\n");
var outline_f22_50_23335=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H116884992\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Stunned myocardium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Relation between hibernation and stunning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Myocardial adaption to ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Coronary autoregulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Myocardial changes associated with hibernation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Altered adrenergic density",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H116884992\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1516\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1516|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/36/31309\" title=\"figure 1\">",
"      Rates of recovery in hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/21/27997\" title=\"figure 2\">",
"      Flow function relationship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1516|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/39/25211\" title=\"table 1\">",
"      Differentiation between hibernation and stunning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=related_link\">",
"      Assessment of myocardial viability by nuclear imaging in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=related_link\">",
"      Clinical implications of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a a6a c href=\"UTD.htm?8/35/8759?source=related_link\" lass=\"medical medical_review\">",
"      Clinical syndromes of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9673?source=related_link\">",
"      Definition and pathogenesis of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=related_link\">",
"      Dobutamine stress echocardiography in the evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=related_link\">",
"      Evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_50_23336="Treatment of androgenetic alopecia in men";
var content_f22_50_23336=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of androgenetic alopecia in men",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/50/23336/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23336/contributors\">",
"     Jeff Donovan, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23336/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23336/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/50/23336/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23336/contributors\">",
"     Maria Hordinsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/50/23336/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23336/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/50/23336/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H533043\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male androgenetic alopecia (also known as male pattern hair loss and male balding) is a common, progressive form of hair loss distinguished by the reduction of terminal hairs on the scalp in a characteristic distribution (",
"    <a class=\"graphic graphic_picture graphicRef83802 graphicRef83804 graphicRef63010 graphicRef83805 \" href=\"UTD.htm?42/14/43242\">",
"     picture 1A-D",
"    </a>",
"    ). The anterior scalp, mid scalp, temporal scalp, and vertex of the scalp are the typical sites of involvement. Hair loss occurs over the course of years.",
"   </p>",
"   <p>",
"    Although androgenetic alopecia is a benign and asymptomatic disorder, cosmetic concerns lead some patients to seek treatment. The primary pharmacologic therapies for men with androgenetic alopecia are topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    . Hair restoration surgery can also result in cosmetic improvement.",
"   </p>",
"   <p>",
"    The treatment of androgenetic alopecia in men will be reviewed here. The pathogenesis, clinical features, and diagnosis of male androgenetic alopecia are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link\">",
"     \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FIRST-LINE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    are the therapeutic agents that have been most extensively studied for the treatment of androgenetic alopecia in men. Both drugs have demonstrated efficacy and high tolerability in placebo-controlled randomized trials, supporting their status as first-line agents. The response to treatment with finasteride or minoxidil varies. While some men achieve cosmetically significant regrowth, others benefit most from the slowing of additional hair loss. Continuation of these drugs is required to maintain the results of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Finasteride",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     Finasteride",
"    </a>",
"    is an oral inhibitor of dihydrotestosterone (DHT) production that is efficacious for male androgenetic alopecia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H533493\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     Finasteride",
"    </a>",
"    competitively inhibits the 5-alpha-reductase type 2 enzyme, and thereby inhibits conversion of testosterone to DHT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/1\">",
"     1",
"    </a>",
"    ]. At a dose of 1",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    finasteride lowers serum and scalp DHT levels by more than 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/2\">",
"     2",
"    </a>",
"    ]. The drug has no affinity for the androgen receptor and does not interfere with testosterone action [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=see_link&amp;anchor=H21714534#H21714534\">",
"     \"Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of placebo-controlled randomized trials identified moderate quality evidence in support of the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    for treatment of androgenetic alopecia in men [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/3\">",
"     3",
"    </a>",
"    ]. After 6 or 12 months of treatment, the mean percentage change in hair count was 9 percent higher among patients treated with finasteride compared with patients who were given placebo (95% CI 8-11 percent). This difference increased over time. After 48 months of therapy, the mean percentage change in hair count was 24 percent (95% CI 18-31 percent) higher in patients treated with finasteride.",
"   </p>",
"   <p>",
"    The proportion of men who achieve clinically significant responses to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    was assessed in two one-year randomized trials that were included in the meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/4\">",
"     4",
"    </a>",
"    ]. A total of 1553 men aged 18 to 41 years with predominantly vertex hair loss were randomly assigned to oral finasteride (1",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo for one year, with blinded extension studies for a second year in 1215 of the men. Finasteride treatment resulted in clinically significant increases in hair count, while treatment with placebo was associated with progressive hair loss. After two years, scalp coverage as assessed by the study investigators was improved in approximately two-thirds of men taking finasteride, versus only 7 percent of men who received placebo. One-third of the men treated with finasteride had the same amount of hair as they did at the start of the study, and only about 1 percent of patients on finasteride lost hair (versus one-third of patients who received placebo). In addition, more men in the finasteride group reported increased satisfaction with their hair after treatment (51 versus 25 percent).",
"   </p>",
"   <p>",
"    Although most published studies documenting the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    have focused on the vertex of the scalp, the efficacy of finasteride is not limited to this area. A randomized trial of 326 men found that the drug was efficacious for frontal scalp hair thinning [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, a subsequent randomized trial found statistically significant hair growth in the vertex,",
"    <span class=\"nowrap\">",
"     anterior/mid,",
"    </span>",
"    frontal, and temporal scalp, with the best results observed in the vertex and",
"    <span class=\"nowrap\">",
"     anterior/mid",
"    </span>",
"    scalp. Age appeared to be relevant in the response to treatment; treatment was more effective in younger men (ages 18 to 41) than older men (ages 41 to 60).",
"   </p>",
"   <p>",
"    In addition to improved hair counts, other factors, such as increases in hair thickness, pigmentation, and length may contribute to the perception of improved scalp coverage during therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/2\">",
"     2",
"    </a>",
"    ]. This concept is supported by a randomized trial that followed men treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    for up to 192 weeks and found that net improvements in hair weight were greater than improvements in hair count [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H335149\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the treatment of male androgenetic alopecia, the recommended dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    is 1 mg per day. The medication may be taken with or without food.",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    should continue for at least 12 months to assess the drug&rsquo;s full effects, and the drug must be continued to maintain efficacy. Hair regrowth will be lost over six to nine months if finasteride is discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H533506\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    has deleterious effects on sexual function. These include erectile dysfunction, decreased libido, and ejaculatory dysfunction. A systematic review of nine trials with a total of 3570 patients found an overall absolute increase in sexual dysfunction of 1.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/3\">",
"     3",
"    </a>",
"    ]. The risk for sexual side effects increases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sexual side effects related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    usually resolve after discontinuation of the medication [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/9\">",
"     9",
"    </a>",
"    ]. However, persistent sexual dysfunction after the discontinuation of finasteride was reported in a survey-based study of 71 men who associated their symptoms of sexual dysfunction with the use of finasteride for hair loss. The mean age of the study participants was 26 years and the mean duration of finasteride use was 28 months. Twenty percent of these men reported continued symptoms for greater than six years after cessation of the medication [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/10\">",
"     10",
"    </a>",
"    ]. Moreover, a follow-up study of 54 of the interviewed men found that 9 to 16 months after the initial survey, 96 percent continued to report sexual side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/11\">",
"     11",
"    </a>",
"    ]. Additional studies are needed to validate these findings and evaluate the frequency with which persistent sexual dysfunction might occur.",
"   </p>",
"   <p>",
"    Other rare side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    include gynecomastia, testicular pain, and depression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/12\">",
"     12",
"    </a>",
"    ]. Side effects are more likely to occur with the typical 5 mg dose used to treat benign prostatic hypertrophy. Although finasteride is teratogenic, the finasteride concentration in semen does not pose a risk to women trying to conceive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23687608\">",
"    <span class=\"h3\">",
"     Precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     Finasteride",
"    </a>",
"    may impact measurement of serum prostate specific antigen (PSA) and effects of the drug on prostate cancer are uncertain. The serum prostate specific antigen (PSA) may decline by as much as 50 percent in men taking the 1 mg dose of finasteride [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/13\">",
"     13",
"    </a>",
"    ]. When the 5 mg dose of finasteride was studied for the chemoprophylaxis of prostate cancer, it reduced the overall incidence of prostate cancer but increased the risk of high grade prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/14\">",
"     14",
"    </a>",
"    ]. It is unclear whether this finding has implications for the safety of long-term treatment with 1 mg of finasteride daily for androgenetic alopecia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=see_link\">",
"     \"Measurement of prostate specific antigen\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=see_link\">",
"     \"Chemoprevention strategies in prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     Finasteride",
"    </a>",
"    is metabolized by the liver. Thus, caution is prudent for use in patients with liver dysfunction. Data are insufficient to conclude whether finasteride influences the risk for male breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=see_link\">",
"     \"Breast cancer in men\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     \"Finasteride: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H956502\">",
"    <span class=\"h2\">",
"     Topical minoxidil",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    is available without a prescription as 2% solution, 5% solution, and 5% foam. Due to evidence in support of greater efficacy of minoxidil 5% solution compared with minoxidil 2% solution in men, use of the 5% concentration is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The subsequent development of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    5% foam offered an alternative vehicle for drug delivery that is preferred by some patients. In addition, unlike minoxidil solution, the foam formulation is free of propylene glycol, a feature that correlates with a lower risk for skin irritation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H956509\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     Minoxidil",
"    </a>",
"    promotes hair growth by increasing the duration of anagen, shortening telogen, and enlarging miniaturized follicles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/18\">",
"     18",
"    </a>",
"    ]. The pathophysiologic mechanism through which minoxidil influences follicular structure and follicular cycling is unclear, and the interpretation of the available literature is complicated by studies with conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/2,18\">",
"     2,18",
"    </a>",
"    ]. Minoxidil is a vasodilator, and the induction of vascular endothelial growth factor (VEGF) may be a mechanism by which minoxidil helps to maintain the vascularity and size of dermal papillae (collections of mesenchymal tissue beneath follicles that contribute to follicular development) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Since the volume of a dermal papilla correlates with the size of the emerging hair follicle, minoxidil-induced support of the dermal papilla may be relevant. In addition, minoxidil is a regulator of potassium ion channels. This function may also contribute to the drug&rsquo;s beneficial effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/18,21\">",
"     18,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H956516\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both 2% and 5%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    solution are more efficacious than placebo in male androgenetic alopecia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/16,17,22\">",
"     16,17,22",
"    </a>",
"    ]. However, the 5% solution is more effective than the 2% formulation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest randomized trial that compared the 5% and 2% solutions, 393 men with androgenetic alopecia were randomly assigned to treatment with 5% or 2% topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    solution or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/16\">",
"     16",
"    </a>",
"    ]. After 48 weeks of therapy, 5% minoxidil was significantly better than the 2% solution or placebo in terms of change from baseline in nonvellus hair count (increase in count of 18.6, 12.7, and 3.9 per cm",
"    <sup>",
"     2",
"    </sup>",
"    , respectively), patient ratings of scalp coverage and treatment benefit, and investigator rating of scalp coverage. Treatment with 5% minoxidil was also associated with an earlier therapeutic response and an improvement in the patients' psychological perceptions of hair loss. However, patients treated with 5% compared with 2% minoxidil reported more pruritus and local irritation.",
"   </p>",
"   <p>",
"    No randomized trials have directly compared the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    5% foam to minoxidil 5% solution. The use of the 5% foam is supported by a 16-week placebo-controlled randomized trial of 352 men [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/17\">",
"     17",
"    </a>",
"    ]. Minoxidil 5% foam was associated with significantly greater improvements in target area terminal hair counts (mean change in terminal hair counts of 20.9 versus 4.7), as well as in scores from patient self-assessments and an investigator global photographic review.",
"   </p>",
"   <p>",
"    As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    , the response to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    is variable. In an early study of 56 patients treated with minoxidil 2% or 3% solution, cosmetically significant improvement occurred in approximately 30 percent of patients. Patients with shorter durations of baldness, smaller areas of baldness, and larger numbers of nonvellus miniaturized hairs appeared to respond best to minoxidil therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H956523\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men utilizing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    for androgenetic alopecia should be advised of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       Minoxidil",
"      </a>",
"      solution is to be used for an indefinite time. Once stopped, any hair regrowth eventually will be lost, often over the course of several months.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       Minoxidil",
"      </a>",
"      is a scalp treatment, not a hair treatment, and must be used exactly as prescribed for maximum benefit.",
"     </li>",
"     <li>",
"      Men should apply 1 mL of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      5% solution or one half of a capful of the 5% foam twice daily to involved areas on a dry scalp. The solution can be spread lightly with a finger; massage is not needed.",
"     </li>",
"     <li>",
"      Hair shedding may occur at the initiation of treatment and is thought to occur as a result of the stimulation of telogen follicles to reenter the anagen phase [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/24\">",
"       24",
"      </a>",
"      ]. The increased hair loss usually resolves within two months. Patients should be warned of this side effect to prevent the premature discontinuation of treatment.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       Minoxidil",
"      </a>",
"      must be used twice a day for at least four months prior to evaluating the initial response to therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/25\">",
"       25",
"      </a>",
"      ]. Hair shedding may occur at the initiation of treatment and usually decreases within two months. Hair growth may be seen within four to eight months and stabilizes at 12 to 18 months. Thus, a full year of treatment is recommended before assessing treatment efficacy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the United States,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    usually is not covered by medical insurance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H956530\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    are infrequent. The most common side effects are contact dermatitis and irritant dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/26\">",
"     26",
"    </a>",
"    ]. When given systemically, minoxidil has antihypertensive properties, but neither 5% nor 2% minoxidil solution alters systolic or diastolic blood pressure, pulse rate, or body weight when applied topically [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/27\">",
"     27",
"    </a>",
"    ]. Nevertheless, due to the potential for systemic absorption when the scalp skin barrier is not intact, caution should be used in patients with cardiovascular disease. Hypertrichosis of the face may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/28\">",
"     28",
"    </a>",
"    ], but generally is not a problem for men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Comparative studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have directly compared the efficacy of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Although high quality studies are needed, the available data from small, incompletely blinded randomized trials suggest that finasteride may be more effective than minoxidil for the induction of hair growth:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only one randomized trial has compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      to the 5% concentration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      that is recommended for male androgenetic alopecia. In the 12-month open randomized trial in 65 men with androgenetic alopecia, a higher proportion of patients treated with finasteride exhibited minimal to dense hair growth than patients treated with minoxidil solution (80 versus 52 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from an evaluator-blinded randomized trial of 99 men with midfrontal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vertex androgenetic alopecia that compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      to the 2% formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      are less straightforward. Although patients and evaluating physicians were more likely to perceive increased hair growth at three months with minoxidil, at 12 months, finasteride was associated with significantly greater increases in hair counts, and the differences in patient and evaluator global assessments of clinical response were not statistically significant (62 versus 56 percent improved on blinded evaluator assessment) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized, open trial of 100 men with androgenetic alopecia evaluated the efficacies of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      alone,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      2% solution alone, finasteride and minoxidil in combination, and finasteride plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      2% shampoo [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/29\">",
"       29",
"      </a>",
"      ]. Increased hair growth was detected in all groups. Patients who received finasteride alone or in combination with minoxidil or ketoconazole had significantly greater improvement than patients who received only minoxidil. The best results were attained by the group treated with both finasteride and minoxidil.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the latter trial found evidence to suggest that combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    may be superior to monotherapy with either agent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/29\">",
"     29",
"    </a>",
"    ], further study is needed to determine whether combination therapy should be routinely recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H335327\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Permanent improvement in androgenetic alopecia can be attained through surgical therapy. Hair transplantation using follicular units has become the mainstay of surgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/32\">",
"     32",
"    </a>",
"    ]. More invasive and complex procedures that aim to reorient large areas of hair-bearing skin, such as scalp reduction and flaps, are now less commonly performed. The ideal candidates for hair transplantation are patients with stable or medically controlled androgenetic alopecia who desire permanent improvements in hair loss and have an adequate reservoir of hair for transplantation.",
"   </p>",
"   <p>",
"    The basic principle governing hair transplantation is that of \"donor dominance.\" Hair follicles removed from non-balding occipital scalp and transplanted into areas affected by androgenetic alopecia will maintain the characteristics of the occipital scalp donor site. Because occipital hair is relatively resistant to androgenetic alopecia, transplanted hairs will remain large caliber hairs. &nbsp;",
"   </p>",
"   <p>",
"    Modern hair transplant techniques rely on the use of \"follicular units\" which are the natural groupings of one to four hair follicles that occur in the scalp. There are two fundamental ways that a hair transplant can be performed using follicular units:",
"    <strong>",
"     follicular unit transplantation",
"    </strong>",
"    (FUT) and",
"    <strong>",
"     follicular unit extraction",
"    </strong>",
"    (FUE).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Follicular unit transplantation",
"      </strong>",
"      &ndash; With FUT, a strip of tissue 8 to 15 mm wide and 20 to 30 cm long is surgically excised from the occipital scalp under local anesthesia. Follicular units are carefully dissected from the tissue strip with the aid of microscopes and then transplanted into areas of androgenetic alopecia. The procedure leaves a thin linear scar in the occipital scalp.",
"     </li>",
"     <li>",
"      <strong>",
"       Follicular unit extraction",
"      </strong>",
"      &ndash; FUE involves the removal of individual follicular units, one by one, from a wide area of the occipital scalp. Although not truly a \"scarless\" technique, FUE does not leave a linear scar and has advantages for men who want to wear their hair very short.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It takes five to eight hours to perform a standard hair transplant session, with FUE taking longer to perform than FUT. A small hair transplant session may involve the transplantation of 800 to 1000 follicular units. A large session (megasession) would involve 3000 to 6000 grafts of follicular units.",
"   </p>",
"   <p>",
"    Patients can continue to lose nontransplanted hairs within susceptible areas following hair transplantation, resulting in diminishing satisfaction with the results. The continuation of medical treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    following a hair transplant procedure may help to limit further loss of preexisting scalp hair. In a randomized trial of 79 men who underwent hair transplantation for androgenetic alopecia, those treated with finasteride 1 mg for four weeks prior to the transplant and for 48 weeks after the transplant achieved better results [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23687420\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple other therapies have been utilized for androgenetic alopecia. Data on the efficacy of these treatments are more limited than for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dutasteride",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     Dutasteride",
"    </a>",
"    , an inhibitor of both type 1 and type 2 5-alpha-reductase, is utilized for the treatment of benign prostatic hyperplasia at a dose of 0.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    ). It is prescribed by some physicians as an off-label treatment for androgenetic alopecia.",
"   </p>",
"   <p>",
"    Compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    is three times more potent of an inhibitor of 5-alpha-reductase type 2 and 100 times more potent of an inhibitor of 5-alpha-reductase type 1. Serum DHT concentrations are reduced by 93 to 94 percent with 0.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of dutasteride compared to around 70 percent with 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of finasteride [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    , fewer studies have evaluated the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    in male androgenetic alopecia. Trials in support of the efficacy of dutasteride include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized, placebo-controlled trial in 416 men compared a range of doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"       dutasteride",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      5 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/35\">",
"       35",
"      </a>",
"      ]. Hair growth showed a dose-response effect with dutasteride, and after 12 and 24 weeks of therapy, dutasteride 2.5 mg daily was more effective than finasteride. This dose of dutasteride is much higher than the standard 0.5 mg dose used for benign prostatic hyperplasia. In this study, 13 percent of men treated with dutasteride 2.5 mg daily reported decreased libido.",
"     </li>",
"     <li>",
"      The results of another randomized trial (n = 153) support the efficacy of the lower dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"       dutasteride",
"      </a>",
"      for males with androgenetic alopecia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/36\">",
"       36",
"      </a>",
"      ]. The trial found that dutasteride (0.5",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      was superior to placebo for the treatment of hair loss; the mean increase in hair counts in men treated with dutasteride was",
"      <span class=\"nowrap\">",
"       12.2/cm",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      compared with",
"      <span class=\"nowrap\">",
"       4.7/cm",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      in men treated with placebo. There was no significant difference in the number of adverse effects reported in both groups. The most common drug-related adverse effect was sexual dysfunction, which was noted in 4 percent of study participants in the dutasteride group and 3 percent of those in the control group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Light therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatments with low level laser light therapy (LLLT) have been marketed for androgenetic alopecia. Although there is limited evidence that LLLT could help a small proportion of patients with androgenetic alopecia, more data are needed before such devices can be routinely recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/37\">",
"     37",
"    </a>",
"    ]. A 26-week randomized trial of a laser comb (HairMax Laser Comb&reg;, Lexington Int.) with 110 subjects found a significantly greater increase in mean terminal hair density in patients treated with the laser comb (three times per week for 8 to 15 minutes), compared with patients treated with a sham device [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/38\">",
"     38",
"    </a>",
"    ]. There was also a statistically significant improvement in the subjects&rsquo; assessment of their own hair at 26 weeks. However, a significant difference in effect was not detected in the investigator subjective global assessments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25182442\">",
"    <span class=\"h2\">",
"     Camouflaging agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of topical camouflaging products can be used to reduce the appearance of hair loss. These include keratin fibers, which are sprinkled onto the hair and a variety of scalp colorants (sprays, lotions, powder cakes). By minimizing the contrast between the color of the scalp and hair, these products reduce the appearance of hair loss. Wigs, toupees, and hairpieces are also effective camouflaging agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25182450\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other treatments for androgenetic alopecia have been studied. A 24-week placebo-controlled randomized trial with 16 male patients showed improvement in hair density using the topical prostaglandin analogue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/42/41635?source=see_link\">",
"     latanoprost",
"    </a>",
"    0.1% [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/39\">",
"     39",
"    </a>",
"    ]. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    2% shampoo may also have some efficacy in treatment of androgenetic alopecia; a small trial of 39 men with androgenetic alopecia showed an increase in hair density after six months of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of other treatments such as carpronium chloride, t-flavone, adenosine, pentadecane, and cepharanthine remains to be fully studied. Data are insufficient to recommend the use of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    and topical fluridil, both of which are topical antiandrogens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23336/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Educational materials on this topic are available for patients (see",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?16/56/17282?source=see_link\">",
"     \"Patient information: Hair loss in men and women (androgenetic alopecia) (Beyond the Basics)\"",
"    </a>",
"    ). We encourage you to print or e-mail this topic review, or to refer patients to our public web site,",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    , which includes this and other topics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Male androgenetic alopecia is a common form of hair loss in men that presents with the loss of terminal hairs in characteristic areas of the scalp (",
"      <a class=\"graphic graphic_picture graphicRef83802 graphicRef83804 graphicRef63010 graphicRef83805 \" href=\"UTD.htm?42/14/43242\">",
"       picture 1A-D",
"      </a>",
"      ). Although the condition is benign and asymptomatic, some men seek treatment due to cosmetic concerns. (See",
"      <a class=\"local\" href=\"#H533043\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For male patients with androgenetic alopecia who desire treatment, we suggest treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      over topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Treatment with minoxidil 5% solution or foam is an alternative first-line therapy that may be preferred by patients who prefer to avoid systemic therapy. The response to treatment with both agents is variable. No high quality randomized trials have directly compared their efficacies. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'First-line therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Men treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      must continue treatment to maintain efficacy. If treatment is discontinued, hair loss will occur within several months after the cessation of therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'First-line therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      is generally well tolerated. Scalp dermatitis is the most common adverse effect of minoxidil. Occasional patients treated with finasteride experience sexual side effects. (See",
"      <a class=\"local\" href=\"#H956530\">",
"       'Adverse effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H533506\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hair transplantation can result in permanent improvements in hair growth in areas of the scalp affected by androgenetic alopecia. Continuing treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      after hair transplantation may help to minimize additional loss of preexisting terminal hairs. (See",
"      <a class=\"local\" href=\"#H335327\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/1\">",
"      Rittmaster RS. Finasteride. N Engl J Med 1994; 330:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/2\">",
"      Price VH. Treatment of hair loss. N Engl J Med 1999; 341:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/3\">",
"      Mella JM, Perret MC, Manzotti M, et al. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol 2010; 146:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/4\">",
"      Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998; 39:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/5\">",
"      Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999; 40:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/6\">",
"      Price VH, Menefee E, Sanchez M, et al. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol 2002; 46:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/7\">",
"      Price VH, Menefee E, Sanchez M, Kaufman KD. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. J Am Acad Dermatol 2006; 55:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/8\">",
"      Olsen EA, Whiting DA, Savin R, et al. Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo. J Am Acad Dermatol 2012; 67:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/9\">",
"      Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol 2002; 12:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/10\">",
"      Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med 2011; 8:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/11\">",
"      Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med 2012; 9:2927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/12\">",
"      Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki A. Finasteride induced depression: a prospective study. BMC Clin Pharmacol 2006; 6:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/13\">",
"      D'Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol 2007; 8:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/14\">",
"      Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/15\">",
"      Shenoy NK, Prabhakar SM. Finasteride and Male Breast Cancer: Does the MHRA Report Show a Link? J Cutan Aesthet Surg 2010; 3:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/16\">",
"      Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/17\">",
"      Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2007; 57:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/18\">",
"      Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004; 150:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/19\">",
"      Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 1998; 138:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/20\">",
"      Li M, Marubayashi A, Nakaya Y, et al. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol 2001; 117:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/21\">",
"      Buhl AE, Conrad SJ, Waldon DJ, Brunden MN. Potassium channel conductance as a control mechanism in hair follicles. J Invest Dermatol 1993; 101:148S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/22\">",
"      Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999; 41:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/23\">",
"      De Villez RL. Topical minoxidil therapy in hereditary androgenetic alopecia. Arch Dermatol 1985; 121:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/24\">",
"      Blumeyer A, Tosti A, Messenger A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges 2011; 9 Suppl 6:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/25\">",
"      Olsen EA, Weiner MS. Topical minoxidil in male pattern baldness: effects of discontinuation of treatment. J Am Acad Dermatol 1987; 17:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/26\">",
"      Ebner H, M&uuml;ller E. Allergic contact dermatitis from minoxidil. Contact Dermatitis 1995; 32:316.",
"     </a>",
"    </li>",
"    <li>",
"     Rogaine extra strength for men (5 percent minoxidil topical solution): for nonprescription use. Summary volume, Pharmacia &amp; Upjohn, Kalamazoo, MI 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/28\">",
"      Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004; 50:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/29\">",
"      Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol 2002; 29:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/30\">",
"      Arca E, A&ccedil;ikg&ouml;z G, Tatan HB, et al. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatology 2004; 209:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/31\">",
"      Saraswat A, Kumar B. Minoxidil vs finasteride in the treatment of men with androgenetic alopecia. Arch Dermatol 2003; 139:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/32\">",
"      Avram M, Rogers N. Contemporary hair transplantation. Dermatol Surg 2009; 35:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/33\">",
"      Leavitt M, Perez-Meza D, Rao NA, et al. Effects of finasteride (1 mg) on hair transplant. Dermatol Surg 2005; 31:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/34\">",
"      Amory JK, Wang C, Swerdloff RS, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 2007; 92:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/35\">",
"      Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006; 55:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/36\">",
"      Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol 2010; 63:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/37\">",
"      Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol 2008; 59:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/38\">",
"      Leavitt M, Charles G, Heyman E, Michaels D. HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled, multicentre trial. Clin Drug Investig 2009; 29:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/39\">",
"      Blume-Peytavi U, L&ouml;nnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol 2012; 66:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23336/abstract/40\">",
"      Pi&eacute;rard-Franchimont C, De Doncker P, Cauwenbergh G, Pi&eacute;rard GE. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology 1998; 196:474.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3321 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_50_23336=[""].join("\n");
var outline_f22_50_23336=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H533043\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FIRST-LINE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Finasteride",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H533493\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H335149\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H533506\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23687608\">",
"      - Precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H956502\">",
"      Topical minoxidil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H956509\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H956516\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H956523\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H956530\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Comparative studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H335327\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23687420\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dutasteride",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Light therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25182442\">",
"      Camouflaging agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25182450\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/3321\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/3321|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/50/6950\" title=\"picture 1A\">",
"      Androgenetic alopecia bitemporal recession",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/52/31559\" title=\"picture 1B\">",
"      Androgenetic alopecia vertex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/36/29253\" title=\"picture 1C\">",
"      Androgenetic alopecia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/47/40692\" title=\"picture 1D\">",
"      Androgenetic alopecia extensive",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10856?source=related_link\">",
"      Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=related_link\">",
"      Breast cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=related_link\">",
"      Chemoprevention strategies in prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=related_link\">",
"      Finasteride: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=related_link\">",
"      Measurement of prostate specific antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/56/17282?source=related_link\">",
"      Patient information: Hair loss in men and women (androgenetic alopecia) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_50_23337="Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis";
var content_f22_50_23337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/50/23337/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23337/contributors\">",
"     John M Burkart, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23337/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/50/23337/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23337/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/50/23337/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23337/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/50/23337/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients on chronic peritoneal dialysis (PD) (including both continuous ambulatory peritoneal dialysis [CAPD] and automated forms of peritoneal dialysis [APD] such as continuous cycler peritoneal dialysis [CCPD]) occasionally have difficulty achieving solute removal goals or maintaining euvolemia. Both inadequate solute removal and volume overload have multiple etiologies.",
"   </p>",
"   <p>",
"    This topic reviews factors that contribute to inadequate solute removal among PD patients and discusses the clearance of particular solutes. This topic also reviews volume overload among PD patients, and provides an approach to evaluating such patients.",
"   </p>",
"   <p>",
"    The factors that regulate solute and water transport across the peritoneal membrane are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33784?source=see_link\">",
"     \"Mechanisms of solute clearance and ultrafiltration in peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following discussion assumes that the peritoneal dialysis prescription was initially adequate and that solute clearance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fluid removal have become impaired over time. A review of the factors that must be considered at the initiation of dialysis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31286?source=see_link\">",
"     \"Choosing a modality for chronic peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H616602798\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among peritoneal dialysis patients, total solute removal or clearance consists of the removal of the solute in question by both dialysis and residual renal clearance. The clearance of a particular solute is often used as a measure of the dialysis dose; in such cases the term clearance refers to the amount of blood that is &ldquo;cleared&rdquo; of a substance over a unit of time. The dialysis dose or clearance may also be expressed by normalizing it to the particular solute&rsquo;s volume of distribution that the solute was cleared from such as",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"   </p>",
"   <p>",
"    Peritoneal",
"    dialysis adequacy is usually quantified in terms of weekly",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    for urea although some still use liters of creatinine",
"    <span class=\"nowrap\">",
"     clearance/week/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p>",
"    The peritoneal dialysis component of solute removal is determined by the final drain volume (instilled volume plus net ultrafiltration volume) and the concentration of the solute in question in the final total drain volume. The rate at which the solute moves from the blood compartment to the dialysate compartment (and conversely from dialysate to blood) by diffusion is called the solute transport rate and varies from patient to patient. The solute transport rate is determined clinically by a Peritoneal Equilibration Test (PET) and by measuring the creatinine saturation of PD fluid",
"    <span class=\"nowrap\">",
"     (Dialysate/Plasma",
"    </span>",
"    ratio for creatinine or",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    creatinine) at four hours. Patients with high solute transport rates typically reach 100 percent saturation of creatinine in the dialysate compared with blood",
"    <span class=\"nowrap\">",
"     (D/P",
"    </span>",
"    ratio for creat = 1.0) faster than a patient who has a low solute transport rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33784?source=see_link&amp;anchor=H2#H2\">",
"     \"Mechanisms of solute clearance and ultrafiltration in peritoneal dialysis\", section on 'General principles of transport across the peritoneal membrane'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ultrafiltration coefficient is the amount of ultrafiltration volume removed per gram of glucose absorbed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INADEQUATE SOLUTE CLEARANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inadequate solute removal (or clearance) among PD patients may have multiple different etiologies. Total solute removal from the body is a function of both residual renal and peritoneal clearance. The peritoneal component is related to the actual effluent volume or drain volume (DV) and the concentration of the particular solute in that DV. As such, when evaluating a patient who presents with suboptimal solute removal,",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    solute diffusion rates and ultrafiltration volumes (and potential convective clearance) from the peritoneum must be reviewed.",
"   </p>",
"   <p>",
"    Solute clearance (or dialysis dose) is typically measured in terms of urea kinetics",
"    <span class=\"nowrap\">",
"     (Kt/V).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    .) Inadequate solute clearance may be suggested by trends in laboratory parameters such as an increasing BUN and plasma creatinine concentration or by the appearance of uremic symptoms despite seemingly successful PD. The differential diagnosis of a patient who appears to be suboptimally dialyzed includes inadequate solute removal, poor compliance with dietary instructions or with the PD prescription, hypercatabolism, loss of residual renal function that has not been replaced with a corresponding increase in peritoneal solute removal, and either a decrease or increase in peritoneal transport.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Poor compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor compliance with dietary restrictions or the prescribed PD regimen is a common cause of signs or symptoms of underdialysis. Often, among such patients, the calculated weekly total solute clearance is adequate because the patient has done the entire dialysis prescription as prescribed on the day that",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    submits the 24 hour dialysate collection for testing, but does not do the entire prescription on other days. In this case, the calculated weekly total solute clearance",
"    <span class=\"nowrap\">",
"     (Kt/V)",
"    </span>",
"    is an overestimate of the true delivered clearance.",
"   </p>",
"   <p>",
"    Among patients on",
"    <span class=\"nowrap\">",
"     APD/CCPD,",
"    </span>",
"    software is often available within the cycler that records the patient&rsquo;s daily dwells and drains so one can get an idea of actual treatments performed. Among patients on CAPD however, it is generally not possible to measure compliance. Although it has been suggested that differences between estimated and measured creatinine generation rates might reveal disparities in the routine performance of exchanges versus performance when collecting dialysate for a",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    measurement, this method has not been found to be clinically useful [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/1\">",
"     1",
"    </a>",
"    ]. One may estimate compliance with the PD prescription by assessing the patient&rsquo;s inventory of dialysis supplies either by the nurse during the yearly home visits or by the person who delivers the patient&rsquo;s dialysis supplies. In the absence of a reliable measure of compliance, the clinician must have a high index of suspicion for this problem especially among CAPD patients. Among non-compliant patients, the 24 hour dialysate collection may or may not be at target and the PET results should be stable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5623?source=see_link\">",
"     \"Peritoneal equilibration test\"",
"    </a>",
"    .) Dietary restrictions should always be reviewed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hypercatabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high protein intake or a hypercatabolic state (as with increased tissue breakdown, metabolic acidosis, or glucocorticoid use) and severe gastrointestinal bleeding can raise the BUN despite good clearances. In such cases, the PET results and the 24 hour urine and dialysate collections are unchanged (and at target if they were initially). Treatment of the underlying cause for hypercatabolism will lower the BUN to the expected values.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9970017\">",
"    <span class=\"h2\">",
"     Loss of residual renal clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among PD patients who have significant residual renal clearance contributing to total solute clearance, a significant decrease in renal function will cause a decrease in total solute clearance, unless there is a corresponding increase in dialysis dose. In such cases, the PET appears unchanged and the 24 hour measurement of solute clearance confirms a decrease in the renal component and no change in the dialysis component.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Decreased peritoneal transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reduction in intrinsic peritoneal membrane transport is a possible cause of decreased solute clearance. Decreased transport is almost always due to a loss of contact surface area rather than a change in the intrinsic transport capacity, although it can occasionally be due to both (as occurs in late stages of encapsulating peritoneal sclerosis), when there are both adhesions and a thickening of the peritoneal membrane which cause a decrease in diffusion rates.",
"   </p>",
"   <p>",
"    Decreased peritoneal transport may be reflected in the PET. In the PET, the ratio of solute concentrations in dialysate and plasma",
"    <span class=\"nowrap\">",
"     (D/P",
"    </span>",
"    ratio) at specific times (t) during the dwell signifies the extent of solute equilibration. In the setting of decreased transport, the",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    values for creatinine are typically lower than those obtained at baseline, often reclassifying the patient as a low or low-average transporter. As an example,",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    urea and creatinine at four hours may be only 0.6 and 0.4, respectively; in comparison, average values in patients with average peritoneal transport are 0.9 and 0.7 (",
"    <a class=\"graphic graphic_figure graphicRef83814 \" href=\"UTD.htm?1/29/1488\">",
"     figure 1",
"    </a>",
"    ). Occasional patients are low transporters at baseline but this is unusual. The exact incidence of reduced peritoneal transport, which is usually due to peritoneal sclerosis or extensive adhesions, is not known; however, reduced transport may play a contributory role in those PD patients who switch to hemodialysis because of inadequate dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial treatment for inadequate solute clearance caused by low peritoneal transport consists of a more intensive dialysis regimen. This usually must be achieved by increasing the volume of inflow dialysate per exchange because the",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    will not increase much with more frequent dwells where contact time is lost with filling and emptying dialysate. However, if the patient on CCPD is not performing a mid day exchange and if increasing the instilled volume per exchange is not tolerated or does not accomplish the goal, then adding a mid day exchange may help to achieve target clearance. If these measures fail to sufficiently improve solute clearances, then transfer of the patient to hemodialysis or combining hemodialysis and PD should be considered. Pharmacologic therapy to improve peritoneal transport and solute clearances has not generally been rewarding. If the change in transport is due to loss of surface area contact due to multiple adhesions, laparoscopic lysis of adhesions may restore contact surface area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9970053\">",
"    <span class=\"h2\">",
"     Increased peritoneal transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among individual patients, an increase in peritoneal transport from a previously established baseline may result in decreased solute removal. This appears counterintuitive, since one expects more solute movement from blood to dialysate as diffusion rates increase. However, solute removal is related to both solute concentration and drain volume. In healthy patients and in PD patients, fluid is continuously absorbed from the peritoneal cavity into post capillary venules and lymphatics (&ldquo;lymphatic absorption&rdquo;). During glucose-containing dwells in rapid transporters, the osmotic gradient which favors ultrafiltration rapidly dissipates due to glucose absorption. Among these patients, if the dwell time is too long much of or all of the ultrafiltrated fluid may be reabsorbed, resulting in low drain volumes. The total solute removal may be less among patients who have peritoneal effluent that is 100 percent saturated but with a low drain volume, then among patients with effluent that is 90 percent saturated but with relatively higher drain volumes.",
"   </p>",
"   <p>",
"    Among patients in whom there is a decrease in solute removal, a followup PET may demonstrate an increased",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    for creatinine at four hours compared with previously obtained values. The increased",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    from an established baseline may reclassify the patient as a high or high-average transporter. As an example,",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    urea and creatinine at four hours may be 0.98 and 0.88, respectively whereas average values in patients with average peritoneal transport are 0.9 and 0.7 (",
"    <a class=\"graphic graphic_figure graphicRef83814 \" href=\"UTD.htm?1/29/1488\">",
"     figure 1",
"    </a>",
"    ). If transport increases and the prescription is not altered, drain volumes and thus solute clearance may be decreased.",
"   </p>",
"   <p>",
"    Occasional patients are high transporters at baseline but this is unusual. Causes of a high baseline transport rate are usually related to a chronic inflammatory state.",
"   </p>",
"   <p>",
"    The rate of transport may transiently increase during an episode of peritonitis due to inflammation-related increases in perfusion of existing capillaries. In such cases, the transport rate usually returns to baseline once peritonitis resolves.",
"   </p>",
"   <p>",
"    In some patients transport status slowly increases over time. This is thought to be due to angiogenesis resulting in an increase in the number of capillaries per unit space (capillary density).",
"   </p>",
"   <p>",
"    The treatment of inadequate solute clearance in rapid transporters is to maintain drain volumes and to replace the rapidly saturated dialysate with fresh dialysate. This can be achieved by increasing the instilled volume per exchange and shortening the dwell time. Shortening the dwell time generally entails adding more glucose-containing exchanges per day (often achieved by adding a mid day exchange).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INADEQUATE ULTRAFILTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among PD patients, the differential diagnosis of volume overload includes dietary indiscretion and changes in cardiovascular status, renal function, peritoneal membrane transport properties or the PD prescription itself.",
"   </p>",
"   <p>",
"    The reported total incidence of impaired ultrafiltration in PD is between 10 and 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, often this is not a &ldquo;true&rdquo; loss of ultrafiltration but rather a mismatch of dwell time to transport type. This problem typically occurs in patients with rapid rates of peritoneal transport and can, in many patients, be treated with more frequent use of hypertonic exchanges or a shortening in PD dwell times. However, impaired ultrafiltration severe enough to require cessation of PD occurs in about 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dietary restrictions of salt and water should never be ignored. Among patients who start PD with residual renal function and significant residual urine volume, dietary salt and water restrictions may not be as important as for patients without residual renal function. However, as residual renal function decreases, failure to restrict salt and water may result in volume overload.",
"   </p>",
"   <p>",
"    During a single dwell of four to six hours, the quantity of peritoneal ultrafiltration is usually inversely proportional to the peritoneal transport of solutes except in conditions of loss of surface area due to severe",
"    <span class=\"nowrap\">",
"     scarring/adhesions",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/4\">",
"     4",
"    </a>",
"    ]. As an example, many patients with low average or low solute transport have excellent ultrafiltration, because the osmotic gradient in the peritoneal cavity is well-maintained throughout the entire dwell period.",
"   </p>",
"   <p>",
"    Conversely, patients with very rapid solute transport achieve osmotic equilibration for creatinine in a few hours (",
"    <a class=\"graphic graphic_figure graphicRef83817 \" href=\"UTD.htm?22/49/23326\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/3\">",
"     3",
"    </a>",
"    ]. Such patients also are rapid absorbers of dialysate glucose, thereby diminishing the osmotic stimulus to ultrafiltration and resulting in low-net ultrafiltration or net fluid absorption. As noted above, total net solute clearance may also decrease because any fluid absorbed into post capillary venules or lymphatics is replete with solute and are thus absorbed back into the circulation. The net effect is a reduction in ultrafiltration volume and net solute clearances, as the solute clearances are a product of",
"    <span class=\"nowrap\">",
"     dialysate/plasma",
"    </span>",
"    concentrations and drain volume (",
"    <a class=\"graphic graphic_figure graphicRef83816 \" href=\"UTD.htm?17/45/18128\">",
"     figure 3",
"    </a>",
"    ). Other common contributing factors include rapid lymphatic absorption and impaired free water transport [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36215?source=see_link\">",
"     \"Rapid transporters on maintenance peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultrafiltration failure due to an elevated peritoneal solute transport may be transient or sustained [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/5\">",
"     5",
"    </a>",
"    ]. Transient increases are seen during episodes of peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/6\">",
"     6",
"    </a>",
"    ], because of an increase in the permeability of the peritoneal membrane to solutes of all sizes, including large proteins. In some cases, repeated episodes of peritonitis lead to a sustained increase in solute transport and a persistent loss of ultrafiltration. Other factors, including the type of buffer used in the dialysate, PD of greater than two years duration (even in the absence of peritonitis), increased exposure to dialysate glucose, and possibly diabetes mellitus and the use of beta blockers may also contribute to impaired ultrafiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/3,7-9\">",
"     3,7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One method to treat inadequate ultrafiltration in high and high-average transporters is to shorten the dwell time of each glucose exchange, keeping the glucose concentration gradient high prior to glucose absorption. This approach explains part of the popularity of automated PD, where the cycler performs three to five short dwell exchanges during the sleeping period. In some patients, nightly peritoneal dwells alone are sufficient to achieve solute clearance (removal) goals, especially among those who have a significant amount of residual renal function. In other patients who need more than just nightly PD exchanges to obtain their solute removal goals, doing a mid day drain followed by another dwell or a dry time will optimize ultrafiltration and at the same time minimize the amount of fluid absorbed from the peritoneal cavity. Alternatively, the excess fluid can be removed by utilizing more hypertonic dextrose solutions. However, exposure to the higher glucose concentration in hypertonic dialysate can cause side effects, such as hyperlipidemia, obesity, glucose intolerance, and increase production of glycosylated proteins and glucose degradation products. One may also consider alternative osmotic agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    , which are slowly absorbed from the peritoneal cavity and therefore tend to have sustained ultrafiltration profiles. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Icodextrin dialysate'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We and other clinicians sometime manage patients with ultrafiltration failure whose rate of diffusive peritoneal membrane transport have increased by temporarily switching to maintenance hemodialysis via a temporary central venous catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The strategy consists of the discontinuation of peritoneal dialysis for four to twelve weeks with subsequent reinstitution of PD. At our center, to prevent adhesion formation, we typically instill 100 to 200 mL of 1.36 percent dialysate containing 3500 IU of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (which is allowed to dwell for thirty minutes and then drained) once or twice a week. In a review of 33 patients treated by this technique, one single rest period allowed peritoneal function to return to earlier levels in 23 individuals (69 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/10\">",
"     10",
"    </a>",
"    ]. The remaining patients required more than one rest period over several years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Icodextrin dialysate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Instillation (usually once daily overnight exchange in CAPD or for the long day dwell in automated PD) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    dialysate, a glucose polymer, may enhance ultrafiltration in patients with high or high-average transport characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Since the compound is relatively inert and slowly absorbed, the osmotic gradient is maintained, thereby providing sustained ultrafiltration. What little is absorbed is eventually metabolized to glucose, such that the caloric load is about equivalent to that of a 2.25 percent dextrose dialysate.",
"   </p>",
"   <p>",
"    A number of randomized controlled studies have found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    is superior to hypertonic glucose solutions in improving ultrafiltration, especially among patients with high or high average rates of peritoneal transport, but also among patients with low-average peritoneal transport [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/14-21\">",
"     14-21",
"    </a>",
"    ]. The European Best Practice Guidelines stated that a 7.5 percent icodextrin-containing solution is recommended for once daily use in patients with inadequate ultrafiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/22\">",
"     22",
"    </a>",
"    ]. This solution should only be used once daily in the longest dwell. Although initially touted as the solution for very long dwells, ultrafiltration does not increase significantly with a dwell that exceeds 10 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     Icodextrin",
"    </a>",
"    has been associated with certain side effects including rash and culture-negative peritonitis (which were principally observed with certain lots). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18632?source=see_link&amp;anchor=H4#H4\">",
"     \"Peritoneal dialysis solutions\", section on 'Osmotic agents'",
"    </a>",
"    .) Diabetic patients who use icodextrin need to be aware that icodextrin may cause falsely elevated blood sugar results with certain home monitoring glucose testing strips, possibly leading to inappropriate therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18632?source=see_link&amp;anchor=H5#H5\">",
"     \"Peritoneal dialysis solutions\", section on 'High molecular weight agents'",
"    </a>",
"    .) Icodextrin metabolites may also interfere with serum assay for amylase activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33381?source=see_link&amp;anchor=H7#H7\">",
"     \"Serum enzymes in patients with renal failure\", section on 'Amylase'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605033540\">",
"    <span class=\"h2\">",
"     Use of diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with significant residual renal function, the administration of diuretics can be used to increase the urine output.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     Furosemide",
"    </a>",
"    may be given at doses up to 500 mg three times per week or once per day in order to obtain substantial urine volumes. Another regimen that may be effective consists of combination therapy with furosemide (200 mg PO twice daily) and a thiazide diuretic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/32/1542?source=see_link\">",
"     metolazone",
"    </a>",
"    , 5 to 10 mg PO twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/24\">",
"     24",
"    </a>",
"    ]. Although they increase urine volume, diuretics do not increase urea or creatinine clearances [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15991?source=see_link\">",
"     \"Evaluation of hypervolemia in peritoneal dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Novel interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Novel methods to prevent the attenuation of the osmotic gradient, thereby increasing ultrafiltration, are also under active investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among seven prevalent patients, ultrafiltration during a 15 hour single dwell exchange with 6.8 percent",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"        icodextrin",
"       </a>",
"       /2.61",
"      </span>",
"      percent glucose was compared with 7.5 percent icodextrin alone and 3.86 percent glucose alone [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/29\">",
"       29",
"      </a>",
"      ]. The combination solution significantly enhanced net ultrafiltration (mean 990 mL) compared with the other solutions.",
"     </li>",
"     <li>",
"      In a pilot study in eight patients, a novel combination dialysate, consisting of 7.5 percent",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"        icodextrin",
"       </a>",
"       /1.36",
"      </span>",
"      percent glucose, was found to provide increased ultrafiltration capability versus that observed with icodextrin 7.5 percent alone [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In animals, the addition to the peritoneal fluid of hyaluronan, a molecule found in interstitial tissue which is a major determinant of the barrier to fluid exchange, significantly decreased peritoneal fluid absorption [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of two",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"       icodextrin",
"      </a>",
"      exchanges per day may increase ultrafiltration. This was suggested by a study of nine patients with poor ultrafiltration who were given two icodextrin exchanges per day for six months [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/30\">",
"       30",
"      </a>",
"      ]. Body weight was reduced in six patients and mean blood pressure was reduced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INADEQUATE SOLUTE CLEARANCE AND ULTRAFILTRATION FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients show a normal or low solute transport and low drain volumes on the PET. In this setting, peritoneal catheter malfunction, loss of aquaporins or extraperitoneal dialysate leakage should be excluded. If these complications are not found, then the cause of ultrafiltration failure may be either enhanced absorption by peritoneal lymphatic vessels or a decline in the peritoneal ultrafiltration coefficient. In general, PD patients who have either of these two problems are the most difficult to manage. Some PD centers perform the peritoneal lymphatic flow test, a maneuver that involves the instillation of macromolecules into the peritoneal cavity followed by measurement of the subsequent rate of their disappearance from the peritoneal cavity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=see_link\">",
"     \"Noninfectious complications of peritoneal dialysis catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Encapsulating peritoneal slerosis (EPS) or sclerosing encapsulating peritonitis (SEP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, one cause of reduced solute transport and drain volumes is a decrease in the peritoneal ultrafiltration coefficient. This is rare, often occurring in conjunction with encapsulating peritoneal sclerosis or EPS. This is also referred to as",
"    <strong>",
"     sclerosing encapsulating peritonitis",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    EPS is characterized by extensive intraperitoneal fibrosis and encasement of bowel loops [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/31\">",
"     31",
"    </a>",
"    ]. It is typically associated with a progressive loss of ultrafiltration, resulting in fluid retention and edema.",
"   </p>",
"   <p>",
"    EPS should not be confused with the generally benign and subclinical peritoneal fibrosis that occurs in most patients on PD. The latter condition is characterized by increased fibrous tissue in the peritoneum, usually without symptoms and almost always without evidence of failure of ultrafiltration. The peritoneal fibrosis in this setting may be induced by episodes of peritonitis (particularly if severe) or may simply be a consequence of a prolonged duration of CAPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pathogenesis and causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, the cause of EPS is believed to be multifactorial and may involve a &ldquo;two-hit&rdquo; process [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/32\">",
"     32",
"    </a>",
"    ]. Possible causes include prior episodes of severe peritonitis, the use of acetate as a dialysate buffer, a reaction to other foreign agents such as plasticizers from catheters, drugs such as beta-blockers, prolonged exposure to glucose degradation products from glucose-containing solutions, withdrawal from PD, and an extended duration of peritoneal dialysis. It appears as if repeated episodes of mild peritonitis are not associated with EPS.",
"   </p>",
"   <p>",
"    The time course of EPS appears to include an early inflammatory stage followed by the sclerosing stage, eventually resulting in an encapsulating cocoon that causes gastrointestinal symptoms such as ileus. Rodent models of EPS provide some insight into the pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. As an example, an \"abdominal cocoon,\" which physically appears similar to EPS, can be induced in rats by sequentially injecting bleach (causing a chemical peritonitis which is the inflammatory stage) and then fresh blood into the peritoneum (one week later). This sequence of events may mimic an episode of bacterial peritonitis followed by bleeding caused either by ongoing inflammation or peritoneal catheter manipulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Incidence, clinical features, and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;EPS is an uncommon finding in patients undergoing PD. The incidence increases with increasing time on PD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/31\">",
"     31",
"    </a>",
"    ]. In a prospective, multicenter study, the incidence and clinical features were evaluated among a total of 1958 patients undergoing PD in 57 facilities in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/35\">",
"     35",
"    </a>",
"    ]. Reported results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      48 patients (2.5 percent) developed EPS; 33 such patients were diagnosed only after discontinuation of PD.",
"     </li>",
"     <li>",
"      An increasing amount of time on PD was associated with an increasing incidence, with the incidence being 0, 0.7, 2.1, 5.9, 5.8, and 17.2 percent for those who had undergone PD for 3, 5, 8, 10, 15, and greater than 15 years, respectively.",
"     </li>",
"     <li>",
"      18 affected patients died (38 percent), while 22 recovered (46 percent); the status of the remainder remained unchanged.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings related to an increasing incidence with prolonged administration of PD have been found in other studies as well [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. In one Australian and New Zealand survey, for example, the incidence of EPS was approximately 0.3, 0.8, and 3.9 percent for patients on peritoneal dialysis for three, five, and eight years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence that the use of biocompatible PD fluids are associated with a decreased incidence of EPS. Some observations suggest that the incidence of EPS may be increasing among patients who resume PD posttransplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/38,40-42\">",
"     38,40-42",
"    </a>",
"    ], which may be due to the following related factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Longer duration of PD pretransplant which may have caused the initial PD membrane damage",
"     </li>",
"     <li>",
"      The cessation of PD posttransplant",
"     </li>",
"     <li>",
"      Lower corticosteroid use post transplant (less reduction of inflammation)",
"     </li>",
"     <li>",
"      The use of calcineurin (pro inflammatory agents) inhibitors as part of the immunosuppressive regimen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    EPS is a slowly progressive, frequently asymptomatic disorder. Clinical features of EPS result from underlying pathogenic processes, particularly ileus, inflammation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peritoneal adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/43\">",
"     43",
"    </a>",
"    ]. Signs and symptoms may include abdominal pain, nausea, loss of appetite, constipation, diarrhea, abdominal mass, ascites, weight loss, vomiting, and fatigue. It is also typically associated with a progressive loss of ultrafiltration, resulting in fluid retention and edema. Unlike other causes associated with these symptoms and signs, EPS is an insidious, gradual, non-acute clinical syndrome. Often one sees a history of an increase in peritoneal transport prior to onset of any GI symptoms.",
"   </p>",
"   <p>",
"    The diagnosis is suspected in the patient with a long history of performing peritoneal dialysis, signs and symptoms consistent with EPS, and a history of an initial progression to a high peritoneal transport state (characterized by increasing",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    Creatinine ratios on PET) often followed by a decrease in",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    creatinine ratios on PET (since the patient may become a low or low average transporter). [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/31,43\">",
"     31,43",
"    </a>",
"    ]. CT scanning is generally recommended as the key imaging technique for the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/31\">",
"     31",
"    </a>",
"    ]. Findings of peritoneal calcification, bowel thickening, bowel tethering, and bowel dilatation are consistent with the diagnosis, although these abnormalities are not diagnostic in the absence of characteristic signs and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnostic confirmation occurs with laparotomy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laparoscopy, showing characteristic peritoneal thickening that encloses intestinal contents. However, since these procedures are invasive and associated with increased risk, imaging techniques are the principal modalities for early diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/44\">",
"     44",
"    </a>",
"    ] and radiographic criteria have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis should be based upon the presence of clinical features resulting from intestinal encapsulation plus characteristic CT or ultrasonographic imaging findings of the peritoneal cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/31,44\">",
"     31,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although frequently unsuccessful, the treatment of EPS has historically entailed cessation of peritoneal dialysis with transfer to hemodialysis (although the disorder may develop or worsen after stopping PD), bowel rest with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN), and (possibly) immunosuppressive therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/35,46-49\">",
"     35,46-49",
"    </a>",
"    ]. Perhaps the best data related to the use of different treatment modalities and outcomes was reported from a prospective study of 48 Japanese patients with EPS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/35\">",
"     35",
"    </a>",
"    ]. Total parenteral nutrition, corticosteroids, and surgery were used either alone or in combination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Zero of three patients treated with TPN alone recovered.",
"     </li>",
"     <li>",
"      39 patients were treated with corticosteroids, with 29 and 6 also receiving TPN or TPN plus surgery, respectively. Fifteen of 39 eventually recovered (39 percent).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       Prednisolone",
"      </a>",
"      was used in all cases. The initial dose ranged from 10 to 40",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      except in nine patients who received pulse",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (0.5 to 1.0",
"      <span class=\"nowrap\">",
"       g/day).",
"      </span>",
"     </li>",
"     <li>",
"      Seven of 12 patients who underwent surgical treatment (with total enterolysis) recovered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In other reports, patients with EPS were successfully treated with corticosteroids alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/47,48,50\">",
"     47,48,50",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    has also been utilized successfully [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/49,51-53\">",
"     49,51-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previously, the prognosis with surgical therapy for EPS was extremely poor. Reported mortality rates with enterectomy and anastomosis have ranged from 40 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/44,54\">",
"     44,54",
"    </a>",
"    ]. However, the use of a novel surgical technique, acute enterolysis, is reportedly associated with markedly improved outcomes. In a retrospective study of 50 patients with EPS who underwent enterolysis, 46 patients (94 percent) had complete relief from bowel obstructive symptoms, with an average follow-up period of 35 months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/55\">",
"     55",
"    </a>",
"    ]. Two patients died and two continued to have mild subacute symptoms. As result, the 2005 recommendations on management of EPS in Japan state that surgery (enterolysis) conducted by an experienced surgeon using appropriate technique is the cornerstone of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23337/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of these small case series, most nephrologists use a short course of glucocorticoids, daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and if clinically needed, parenteral nutrition for the treatment of EPS. Further study is required to understand the optimal therapy in this condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32333769\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic peritoneal dialysis can be complicated by problems with either inadequate solute clearance or impaired ultrafiltration. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inadequate solute removal is defined as an increasing BUN and plasma creatinine concentration or the appearance of uremic symptoms despite seemingly successful PD. Inadequate solute clearance may be caused by poor compliance, hypercatabolism, loss of residual renal function, and either a decrease or increase in peritoneal transport. These causes can be distinguished in part by performing a peritoneal equilibration (PET) test. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Inadequate solute clearance'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5623?source=see_link\">",
"       \"Peritoneal equilibration test\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The initial treatment for inadequate solute clearance caused by low peritoneal transport is more intensive dialysis which is achieved by increasing the volume of inflow dialysate per exchange and possibly the number of",
"      <span class=\"nowrap\">",
"       exchanges/day.",
"      </span>",
"      Among patients on automated peritoneal dialysis (APD) such as continuous cycling peritoneal dialysis (CCPD) who are not performing a mid day exchange, adding a mid day exchange may help. If these measures fail to sufficiently improve solute clearances, then transfer of the patient to hemodialysis or combination of HD and PD should be considered. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Decreased peritoneal transport'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among PD patients, volume overload may have multiple causes including but not limited to excessive dietary salt and water intake, compliance with ordered PD prescription, loss of residual renal volume that is not replaced with an increase in peritoneal ultrafiltration, loss of peritoneal aquaporin channels, mechanical problems, and a change in peritoneal transport. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Inadequate ultrafiltration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Impaired peritoneal ultrafiltration is characterized by a persistently low drain volume after four hours of dwell time. Impaired ultrafiltration is usually caused by rapid transport of glucose, which may be transient, due to an acute episode of peritonitis, or sustained usually due to changes in the peritoneal membrane. Patients with impaired ultrafiltration may be treated by shortening the dwell time of each exchange, or by using more frequent hypertonic exchanges. Other options include instillation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"       icodextrin",
"      </a>",
"      dialysate, or the use of diuretics in patients with residual renal function. Occasionally patients with ultrafiltration failure may require maintenance hemodialysis via a temporary central venous catheter. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Inadequate ultrafiltration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Icodextrin dialysate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The combination of normal or low solute transport and low drain volumes suggest peritoneal catheter malfunction, extraperitoneal dialysate leakage, enhanced absorption by peritoneal lymphatic vessels loss of peritoneal aquaporin water transport or a decline in the peritoneal ultrafiltration coefficient. A decrease in the peritoneal ultrafiltration coefficient is rare, and may occur in conjunction with Encapsulating Peritoneal Sclerosis (EPS). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Inadequate solute clearance and ultrafiltration failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EPS is characterized by extensive intraperitoneal fibrosis and encasement of bowel loops and is associated with a progressive loss of ultrafiltration, resulting in fluid retention and edema. Possible contributors include prior episodes of severe peritonitis, the use of acetate as a dialysate buffer, a reaction to other foreign agents such as plasticizers from catheters, the administration of drugs such as beta-blockers, premature withdrawal from PD, and prolonged time on PD. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pathogenesis and causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Signs and symptoms of EPS include abdominal pain, nausea, loss of appetite, constipation, diarrhea, an abdominal mass, ascites, weight loss, vomiting, and fatigue. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Incidence, clinical features, and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of EPS is generally made by CT scanning which demonstrates peritoneal calcification, bowel thickening, bowel tethering, and bowel dilatation. Diagnostic confirmation is by laparotomy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      laparoscopy, but these invasive procedures are rarely performed for this purpose. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Incidence, clinical features, and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of EPS often entails cessation of peritoneal dialysis with transfer to hemodialysis (although the disorder may develop or worsen after stopping PD), bowel rest with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      (TPN), and (possibly) immunosuppressive therapy, (possibly) anti-fibrotic therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgery. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/1\">",
"      Burkart JM, Bleyer AJ, Jordan JR, Zeigler NC. An elevated ratio of measured to predicted creatinine production in CAPD patients is not a sensitive predictor of noncompliance with the dialysis prescription. Perit Dial Int 1996; 16:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/2\">",
"      Tzamaloukas, AH. Inadequacy of dialysis and infectious complications of continuous ambulatory peritoneal dialysis (CAPD): Diagnosis, management and prevention. AKF Nephrol 1991; 8:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/3\">",
"      Smit W, Schouten N, van den Berg N, et al. Analysis of the prevalence and causes of ultrafiltration failure during long-term peritoneal dialysis: a cross-sectional study. Perit Dial Int 2004; 24:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/4\">",
"      Pollock CA, Ibels LS, Hallett MD, et al. Loss of ultrafiltration in continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1989; 9:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/5\">",
"      Margetts PJ, Churchill DN. Acquired ultrafiltration dysfunction in peritoneal dialysis patients. J Am Soc Nephrol 2002; 13:2787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/6\">",
"      Albrektsen GE, Wider&oslash;e TE, Nilsen TI, et al. Transperitoneal water transport before, during, and after episodes with infectious peritonitis in patients treated with CAPD. Am J Kidney Dis 2004; 43:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/7\">",
"      Stegmayr BG. Beta-blockers may cause ultrafiltration failure in peritoneal dialysis patients. Perit Dial Int 1997; 17:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/8\">",
"      Krediet RT. Beta-blockers and ultrafiltration failure. Perit Dial Int 1997; 17:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/9\">",
"      Davies SJ, Brown EA, Frandsen NE, et al. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005; 67:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/10\">",
"      Selgas R, Bajo MA, Castro MJ, et al. Managing ultrafiltration failure by peritoneal resting. Perit Dial Int 2000; 20:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/11\">",
"      Zhe XW, Tian XK, Cheng L, Wang T. Effects of peritoneal resting on peritoneal fluid transport kinetics. Perit Dial Int 2007; 27:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/12\">",
"      Wilkie ME, Plant MJ, Edwards L, Brown CB. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival. Perit Dial Int 1997; 17:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/13\">",
"      Konings CJ, Kooman JP, van der Sande FM, Leunissen KM. Fluid status in peritoneal dialysis: what's new? Perit Dial Int 2003; 23:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/14\">",
"      Finkelstein F, Healy H, Abu-Alfa A, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 2005; 16:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/15\">",
"      Mistry CD, Gokal R. Optimal use of glucose polymer (icodextrin) in peritoneal dialysis. Perit Dial Int 1996; 16 Suppl 1:S104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/16\">",
"      Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 1994; 46:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/17\">",
"      Wolfson M, Piraino B, Hamburger RJ, et al. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002; 40:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/18\">",
"      Davies SJ, Woodrow G, Donovan K, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14:2338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/19\">",
"      Rodr&iacute;guez-Carmona A, P&eacute;rez Font&aacute;n M, Garc&iacute;a L&oacute;pez E, et al. Use of icodextrin during nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing the peritoneal glucose load: a randomized crossover study. Perit Dial Int 2007; 27:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/20\">",
"      Lin A, Qian J, Li X, et al. Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid. Clin J Am Soc Nephrol 2009; 4:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/21\">",
"      Takatori Y, Akagi S, Sugiyama H, et al. Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial. Clin J Am Soc Nephrol 2011; 6:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/22\">",
"      European Best Practice Guidelines for peritoneal dialysis. Nephrol Dial Transplant 2005; 20(Suppl 9):3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/23\">",
"      Jeloka TK, Ersoy FF, Yavuz M, et al. What is the optimal dwell time for maximizing ultrafiltration with icodextrin exchange in automated peritoneal dialysis patients? Perit Dial Int 2006; 26:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/24\">",
"      Tzamaloukas AH. Avoiding the use of hypertonic dextrose dialysate in peritoneal dialysis. Semin Dial 2000; 13:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/25\">",
"      Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 2001; 59:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/26\">",
"      Dallas F, Jenkins SB, Wilkie ME. Enhanced ultrafiltration using 7.5% icodextrin/1.36% glucose combination dialysate: a pilot study. Perit Dial Int 2004; 24:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/27\">",
"      Wang T, Cheng HH, Heimb&uuml;rger O, et al. Hyaluronan decreases peritoneal fluid absorption: effect of molecular weight and concentration of hyaluronan. Kidney Int 1999; 55:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/28\">",
"      Rosengren BI, Carlsson O, Rippe B. Hyaluronan and peritoneal ultrafiltration: a test of the \"filter-cake\" hypothesis. Am J Kidney Dis 2001; 37:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/29\">",
"      Freida P, Galach M, Divino Filho JC, et al. Combination of crystalloid (glucose) and colloid (icodextrin) osmotic agents markedly enhances peritoneal fluid and solute transport during the long PD dwell. Perit Dial Int 2007; 27:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/30\">",
"      Dousdampanis P, Trigka K, Chu M, et al. Two icodextrin exchanges per day in peritoneal dialysis patients with ultrafiltration failure: one center's experience and review of the literature. Int Urol Nephrol 2011; 43:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/31\">",
"      Brown EA, Van Biesen W, Finkelstein FO, et al. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD. Perit Dial Int 2009; 29:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/32\">",
"      Kawaguchi Y, Tranaeus A. A historical review of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25 Suppl 4:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/33\">",
"      Levine S, Saltzman A. Abdominal cocoon: an animal model for a complication of peritoneal dialysis. Perit Dial Int 1996; 16:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/34\">",
"      Io H, Hamada C, Ro Y, et al. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004; 65:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/35\">",
"      Kawanishi H, Kawaguchi Y, Fukui H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004; 44:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/36\">",
"      Nomoto Y, Kawaguchi Y, Kubo H, et al. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis 1996; 28:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/37\">",
"      Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998; 13:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/38\">",
"      Brown MC, Simpson K, Kerssens JJ, et al. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol 2009; 4:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/39\">",
"      Johnson DW, Cho Y, Livingston BE, et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int 2010; 77:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/40\">",
"      Korte MR, Yo M, Betjes MG, et al. Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. Nephrol Dial Transplant 2007; 22:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/41\">",
"      Fieren MW, Betjes MG, Korte MR, Boer WH. Posttransplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int 2007; 27:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/42\">",
"      de Freitas DG, Augustine T, Brown EA, et al. Encapsulating peritoneal sclerosis following renal transplantation - the UK experience. Am J Transplant 2007; 7:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/43\">",
"      Nakamoto H. Encapsulating peritoneal sclerosis--a clinician's approach to diagnosis and medical treatment. Perit Dial Int 2005; 25 Suppl 4:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/44\">",
"      Kawaguchi Y, Saito A, Kawanishi H, et al. Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int 2005; 25 Suppl 4:S83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/45\">",
"      Tarzi RM, Lim A, Moser S, et al. Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis. Clin J Am Soc Nephrol 2008; 3:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/46\">",
"      Junor BJ, McMillan MA. Immunosuppression in sclerosing peritonitis. Adv Perit Dial 1993; 9:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/47\">",
"      Mori Y, Matsuo S, Sutoh H, et al. A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Am J Kidney Dis 1997; 30:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/48\">",
"      Martins LS, Rodrigues AS, Cabrita AN, Guimaraes S. Sclerosing encapsulating peritonitis: a case successfully treated with immunosuppression. Perit Dial Int 1999; 19:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/49\">",
"      Summers AM, Clancy MJ, Syed F, et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int 2005; 68:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/50\">",
"      Wong CF, Beshir S, Khalil A, et al. Successful treatment of encapsulating peritoneal sclerosis with azathioprine and prednisolone. Perit Dial Int 2005; 25:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/51\">",
"      Eltoum MA, Wright S, Atchley J, Mason JC. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int 2006; 26:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/52\">",
"      Guest S. Tamoxifen therapy for encapsulating peritoneal sclerosis: mechanism of action and update on clinical experiences. Perit Dial Int 2009; 29:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/53\">",
"      Korte MR, Fieren MW, Sampimon DE, et al. Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. Nephrol Dial Transplant 2011; 26:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/54\">",
"      Lee, HY, Kim, BS, Choi, HY, et al. Sclerosing encapsulating peritonitis as a complication of long-term continuous ambulatory peritoneal dialysis in Korean. Nephrology 2003; 8(Suppl 2):S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23337/abstract/55\">",
"      Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25 Suppl 4:S39.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1973 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-3ADB073D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_50_23337=[""].join("\n");
var outline_f22_50_23337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32333769\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H616602798\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INADEQUATE SOLUTE CLEARANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Poor compliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hypercatabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9970017\">",
"      Loss of residual renal clearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Decreased peritoneal transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9970053\">",
"      Increased peritoneal transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INADEQUATE ULTRAFILTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Icodextrin dialysate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H605033540\">",
"      Use of diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Novel interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INADEQUATE SOLUTE CLEARANCE AND ULTRAFILTRATION FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Encapsulating peritoneal slerosis (EPS) or sclerosing encapsulating peritonitis (SEP)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Incidence, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32333769\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1973\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1973|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/29/1488\" title=\"figure 1\">",
"      PET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/49/23326\" title=\"figure 2\">",
"      High vs low transport in peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/45/18128\" title=\"figure 3\">",
"      PET rate of transport",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=related_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31286?source=related_link\">",
"      Choosing a modality for chronic peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/39/15991?source=related_link\">",
"      Evaluation of hypervolemia in peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33784?source=related_link\">",
"      Mechanisms of solute clearance and ultrafiltration in peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=related_link\">",
"      Noninfectious complications of peritoneal dialysis catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18632?source=related_link\">",
"      Peritoneal dialysis solutions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5623?source=related_link\">",
"      Peritoneal equilibration test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36215?source=related_link\">",
"      Rapid transporters on maintenance peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33381?source=related_link\">",
"      Serum enzymes in patients with renal failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_50_23338="Treatment and prevention of post-transplant lymphoproliferative disorders";
var content_f22_50_23338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of post-transplant lymphoproliferative disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/50/23338/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23338/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23338/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23338/contributors\">",
"     Mariell Jessup, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/50/23338/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23338/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23338/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/50/23338/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23338/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/50/23338/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/50/23338/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-transplant lymphoproliferative disorders (PTLD) are lymphoid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plasmacytic proliferations that occur in the setting of solid organ or allogeneic hematopoietic cell transplantation as a result of immunosuppression. They are among the most serious and potentially fatal complications of transplantation. While the majority appears to be related to the presence of Epstein-Barr virus (EBV), EBV-negative disease does occur. Three general types of PTLD have been described in transplant recipients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Early lesion",
"      </strong>",
"      (ie, plasmacytic hyperplasia and infectious mononucleosis-like PTLD) &mdash; This presents as an infectious mononucleosis-type acute illness characterized by polyclonal B cell proliferation with no evidence to suggest malignant transformation.",
"     </li>",
"     <li>",
"      <strong>",
"       Polymorphic PTLD",
"      </strong>",
"      &mdash; Polymorphic PTLD are polyclonal or monoclonal lymphoid infiltrates that demonstrate evidence of malignant transformation but do not meet all of the criteria for one of the B cell or",
"      <span class=\"nowrap\">",
"       T/NK",
"      </span>",
"      cell lymphomas recognized in immunocompetent patients.",
"     </li>",
"     <li>",
"      <strong>",
"       Monomorphic PTLD",
"      </strong>",
"      &mdash; Monomorphic PTLD are monoclonal lymphoid proliferations that meet the criteria for one of the B cell or",
"      <span class=\"nowrap\">",
"       T/NK",
"      </span>",
"      cell lymphomas recognized in immunocompetent patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These conditions lie along a continuum of disease and are categorized by the 2008 WHO classification system as PTLD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/1\">",
"     1",
"    </a>",
"    ]. Of importance, small B cell lymphoid neoplasms (eg, follicular lymphomas, small lymphocytic lymphoma) and marginal zone (MALT) lymphomas arising in the post-transplant setting are",
"    <strong>",
"     not",
"    </strong>",
"    considered PTLD.",
"   </p>",
"   <p>",
"    The treatment and prevention of PTLD following solid organ and allogeneic hematopoietic cell transplant will be reviewed here. The diagnosis of PTLD and the development of other secondary malignancies following transplant are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28280?source=see_link\">",
"     \"Malignancy after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the development of PTLD is related to the degree of immunosuppression and infection with Epstein-Barr virus (EBV) and cytomegalovirus (CMV), prevention largely relies upon limiting patient exposure to aggressive immunosuppressive regimens, rapid withdrawal and tapering of agents required for graft acceptance, and anti-viral prophylaxis. Attention to such measures may lessen the incidence of PTLD. In addition, many transplant centers have incorporated EBV monitoring into the routine evaluation of patients at high risk for PTLD with preemptive treatment of PTLD at the time of viral reactivation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link&amp;anchor=H17288449#H17288449\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\", section on 'Measurement of Epstein-Barr viral load'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13166231\">",
"    <span class=\"h2\">",
"     Tapering immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance immunosuppressive therapy is used in the transplant setting to help prevent acute rejection, loss of the allograft, and graft-versus-host disease. While the degree of immunosuppression required and the timing of immunosuppression withdrawal differs with the clinical setting, there is general agreement that more aggressive withdrawal of immunosuppression to maintenance target concentrations is associated with lower incidence of PTLD.",
"   </p>",
"   <p>",
"    As an example, a relatively high incidence of PTLD was found with the introduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (FK506). Therefore, the aggressive tapering of this agent may limit the development of this disorder. In one review of 82 children who received renal allografts with tacrolimus-based regimens, the incidence of PTLD was 17 percent (5 of 29 patients) among patients transplanted between 1989 and 1992 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence fell to 4 percent (2 of 53 cases) for those transplanted from early 1993 to 1996, a finding attributed in part to a policy of aggressive tapering of tacrolimus (and corticosteroids) to a lower maintenance target trough concentration of 5 to 9",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Details regarding the use of immunosuppressive therapy post-transplant are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18458?source=see_link\">",
"     \"Induction and maintenance of immunosuppressive therapy in cardiac transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12474?source=see_link\">",
"     \"Maintenance immunosuppression following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35385?source=see_link\">",
"     \"Treatment of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13166266\">",
"    <span class=\"h2\">",
"     Antiviral prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high incidence of PTLD among EBV-seronegative recipients of EBV-seropositive donor organs suggests that the ability to suppress primary EBV infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    detect and subsequently treat early infection may minimize the subsequent development of PTLD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Support for the use of antiviral prophylaxis in the prevention of PTLD comes from retrospective studies and single-arm prospective studies described below. Antiviral prophylaxis is commonly administered in the post-transplant period to prevent viral reactivation. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link&amp;anchor=H21#H21\">",
"     \"Prophylaxis of infections in solid organ transplantation\", section on 'Viral infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The effectiveness of both the prophylactic use of antiviral agents and the early detection of primary EBV infection with polymerase chain reaction (PCR) followed by antiviral therapy and lowering of the immunosuppressive regimen was evaluated in 40 children receiving a liver allograft [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/4\">",
"       4",
"      </a>",
"      ]. The schedule of antiviral prophylaxis was determined by risk to develop PTLD as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      High risk patients (eg, donor EBV-positive, recipient EBV-negative) were administered a minimum of 100 days of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      (6 to 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day).",
"     </li>",
"     <li>",
"      Low risk patients (eg, donor EBV-negative, recipient EBV-positive or -negative; donor and recipient EBV-positive) received intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      only during the period of hospitalization followed by oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day).",
"      <br/>",
"      <br/>",
"      Target",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      levels were lowered to 2 to 5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in patients in whom a rising viral copy number was detected by PCR performed once per month. PTLD, which was defined as histologic evidence of B cell proliferation, was treated with the reinstitution of intravenous ganciclovir and the withdrawal of tacrolimus. At a mean follow-up of approximately 260 days, the following results were reported:",
"     </li>",
"     <li>",
"      Among 18 high-risk children, there were no cases of PTLD and one case of EBV infection (which resolved).",
"     </li>",
"     <li>",
"      Among 22 low-risk patients, two cases of PTLD occurred, both of which resolved after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      was stopped; there was one case of EBV increase, which also resolved.",
"      <br/>",
"      <br/>",
"      The 5 percent incidence of PTLD with this regimen compares favorably to the incidence of 10 percent previously reported from this same center. This lower incidence combined with the finding that no high-risk patient developed PTLD suggests that aggressive preemptive therapy and frequent monitoring for early EBV infection, which (when detected) is managed by intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      and reductions in immunosuppression, may lower the incidence of PTLD. (See",
"      <a class=\"local\" href=\"#H260801294\">",
"       'Preemptive treatment of viral reactivation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A retrospective multicenter case-control study of renal transplant recipients also found that prophylactic antiviral therapy reduced the risk of PTLD [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/7\">",
"       7",
"      </a>",
"      ]. In this report of 100 biopsy-confirmed cases and 375 matched controls, the risk of PTLD during the first year post-transplant decreased by 38 percent for every 30 days of treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      (OR of 0.62, 95% CI 0.38-1.0). The addition of immune globulin to ganciclovir does not appear to provide added benefit to ganciclovir alone among patients at increased risk for PTLD [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In one large retrospective database study, use of prophylaxis with anti-CMV immunoglobulin during the first four months after kidney transplantation significantly reduced the incidence of PTLD during the first year post-transplant, but not in the subsequent five years [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/9\">",
"       9",
"      </a>",
"      ]. This may have been due to temporary anti-EBV protection from the substantial anti-EBV reactivity present in the immunoglobulin preparations employed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260801294\">",
"    <span class=\"h2\">",
"     Preemptive treatment of viral reactivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many transplant centers have incorporated EBV monitoring into the routine evaluation of patients at high risk for PTLD and preemptive treatment of PTLD at the time of viral reactivation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    or reduced immunosuppression. Of the various treatment options, the approach of using preemptive rituximab therapy seems most appropriate for patients at high risk of EBV-associated PTLD and has been utilized at a number of centers with success. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one prospective study of high-risk patients undergoing partially T cell depleted allogeneic hematopoietic cell transplantation (HCT), a single infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      given to 15 patients with EBV reactivation (ie, &ge;1000 EBV genome",
"      <span class=\"nowrap\">",
"       equivalents/mL)",
"      </span>",
"      resulted in complete response in 14, as evidenced by prevention of PTLD and complete clearance of EBV-DNA from the peripheral blood [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study of 70 children undergoing reduced intensity conditioning with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      T cell depletion followed by allogeneic HCT prospectively monitored EBV viral load [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/11\">",
"       11",
"      </a>",
"      ]. Patients who developed a viral load &gt;40,000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      within three months of transplant or with a low CD3 count were treated preemptively with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . When compared with historical controls, this approach was associated with a lower incidence of PTLD (1.4 versus 21.7 percent), especially among viremic patients (3 versus 63 percent). Although patients who received rituximab had significantly delayed B cell reconstitution, this was not associated with an increase in infectious mortality. &nbsp;",
"     </li>",
"     <li>",
"      In another study, reduction or suspension of immunosuppression was employed when EBV reactivation was detected (ie, &ge;300 genomic copies per 10",
"      <sup>",
"       5",
"      </sup>",
"      peripheral blood mononuclear cells) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/12\">",
"       12",
"      </a>",
"      ]. This preemptive modulation of immunosuppression was accomplished in 28 patients without negatively influencing transplant-related mortality, overall, or event-free survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transplant centers and society guidelines differ in their recommendations regarding EBV surveillance following transplant. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link&amp;anchor=H17288449#H17288449\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\", section on 'Measurement of Epstein-Barr viral load'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17288044\">",
"    <span class=\"h1\">",
"     PRETREATMENT ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pretreatment evaluation of patients with PTLD both determines the extent of the disease and provides information about the individual's comorbidities that are likely to have an impact on treatment options.",
"   </p>",
"   <p>",
"    While most elements of the patient&rsquo;s history are pertinent to the problem at hand, some are particularly relevant to treatment selection. These include the patient&rsquo;s performance status (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 1",
"    </a>",
"    ) and comorbidities, the type of transplant, the immunosuppressive regimen used, the status of the graft, the potential impact of graft failure, and the presence of graft-versus-host disease (in hematopoietic cell transplant recipients).",
"   </p>",
"   <p>",
"    In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with PTLD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count with differential, chemistries with liver and renal function and electrolytes, lactate dehydrogenase (LDH), albumin, HIV, hepatitis B, Epstein-Barr virus (EBV) serology with quantitative polymerase chain reaction (PCR), and cytomegalovirus (CMV) PCR. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"       \"Hepatitis B virus reactivation associated with immunosuppression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A contrast-enhanced computed tomography (CT) scan of the chest, abdomen, and pelvis should be performed. This study provides critical information on the measurement of disease prior to treatment, and aids in staging [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/13\">",
"       13",
"      </a>",
"      ]. When available, we suggest obtaining a combined positron emission tomography",
"      <span class=\"nowrap\">",
"       (PET)/CT",
"      </span>",
"      scan as a measure of disease activity [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H13#H13\">",
"       \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Routine imaging studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Assessment of the function of the transplanted organ.",
"     </li>",
"     <li>",
"      Unilateral bone marrow aspiration and biopsy is suggested for patients with cytopenias.",
"     </li>",
"     <li>",
"      If involvement of the central nervous system is suspected, further evaluation should include gadolinium-enhanced magnetic resonance imaging (MRI) of the head and cerebral spinal fluid (CSF) analysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link&amp;anchor=H21103720#H21103720\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\", section on 'Central nervous system lymphoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A study of cardiac function (eg, echocardiogram or MUGA) should be performed for patients with a history of cardiac disease (and no heart transplant) and for those who plan to undergo anthracycline-based chemotherapy (eg, R-CHOP).",
"     </li>",
"     <li>",
"      Men and women with child-bearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"       \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260803824\">",
"    <span class=\"h2\">",
"     Choice of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of PTLD has varied significantly according to the PTLD subtype and the type of transplant, as well as from institution to institution [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The main options for initial treatment are reduction of immunosuppression, immunotherapy with the CD20 monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , chemotherapy, radiation therapy, or a combination of these. Other treatments, such as adoptive immunotherapy with EBV specific cytotoxic T cells, are generally reserved for persistent disease despite initial therapy or for those patients treated at selective sites capable of performing these types of treatments. A choice among therapies must take into consideration the aggressiveness of the PTLD, the expected time to response of individual therapies, and associated toxicities. Of importance, rituximab is only effective in CD20 positive PTLD. &nbsp;",
"   </p>",
"   <p>",
"    The two main goals of therapy are eradication of the PTLD and preservation of graft function. Not uncommonly, these goals conflict and one must take precedence. As an example, reduction of immunosuppression is commonly employed for PTLD eradication, but increases the risk of graft rejection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    graft-versus-host disease. Reduction of immunosuppression may be preferred when alternative organ support is available (eg, renal or",
"    <span class=\"nowrap\">",
"     renal/pancreas",
"    </span>",
"    transplant). In contrast, there will be cases in which worsening graft function in vital organs (eg, heart transplant) necessitates continued immunosuppression and dictates the need for alternative therapies.",
"   </p>",
"   <p>",
"    The World Health Organization classification of tumors of the hematopoietic and lymphoid tissues uses morphologic, immunophenotypic, genetic, and clinical features to define four main categories of PTLD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/1\">",
"     1",
"    </a>",
"    ]. Our initial management is largely dependent upon the type of PTLD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Early lesions",
"      </strong>",
"      &mdash; For most patients with early lesions, we suggest reduction of immunosuppression alone rather than in combination with other therapies. Other agents are generally reserved for those patients with residual disease despite reduced immunosuppression or for those who cannot tolerate reduction of immunosuppression. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Early lesions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Polymorphic PTLD",
"      </strong>",
"      &mdash; For most patients with polymorphic PTLD that expresses CD20 (CD20+ PTLD), we suggest the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in addition to reduction of immunosuppression, as tolerated, rather than reduction of immunosuppression alone. Chemotherapy and surgery may be considered in addition for a subset of patients with systemic or localized disease, respectively. (See",
"      <a class=\"local\" href=\"#H260803914\">",
"       'Polymorphic PTLD'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Monomorphic PTLD",
"      </strong>",
"      &mdash; For patients with monomorphic CD20+ PTLD, we suggest the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , either alone or in combination with chemotherapy in addition to reduction of immunosuppression, if possible. Single agent rituximab may be considered for patients who have minimal symptoms and for those who are not candidates for initial chemotherapy (eg, poor performance status). All other patients with CD20+ PTLD are offered rituximab plus combination chemotherapy (eg, CHOP), administered concurrently or sequentially. Patients whose tumors do not express CD20 are not candidates for rituximab therapy and are treated with combination chemotherapy plus reduction of immunosuppression, if possible. Surgery is reserved for patients with complications such as perforation or obstruction. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Monomorphic PTLD'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Classical Hodgkin lymphoma-like PTLD",
"      </strong>",
"      &mdash; Classical Hodgkin lymphoma-like PTLD is the least common form of PTLD, and there is a paucity of data regarding management. For most patients with classical Hodgkin lymphoma-like PTLD we suggest management with chemotherapy with or without radiation therapy according to protocols used for classical Hodgkin lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=see_link\">",
"       \"Overview of the treatment of classical Hodgkin lymphoma in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our approach is generally consistent with practice guidelines proposed by the National Comprehensive Cancer Network (NCCN), the British Committee for Standards in Haematology, the British Transplantation Society, and the European best practice guidelines for renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. While these guidelines differ in detail, they all recognize a benefit from reduction of immunosuppression and the need to balance this with the risk of graft rejection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Early lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early lesions are characterized by polyclonal B cell proliferation with no evidence to suggest malignant transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/1\">",
"     1",
"    </a>",
"    ]. For most patients with early lesions, we suggest reduction of immunosuppression alone rather in combination with immunotherapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ), chemotherapy, or antivirals. This preference is largely based upon uncontrolled trials that have suggested the efficacy of reduction of immunosuppression and the desire to avoid potential harms associated with more intensive therapy. Rituximab may be considered for those patients with CD20 positive PTLD with residual disease despite reduction of immunosuppression or for those who cannot tolerate reduction of immunosuppression. While antiviral prophylaxis may decrease the incidence of PTLD, antiviral therapy has yet to demonstrate convincing efficacy in the treatment of PTLD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13166266\">",
"     'Antiviral prophylaxis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Reduction in immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduction of immunosuppression should be incorporated into the initial management of all patients with PTLD unless concerns regarding graft rejection or graft-versus-host disease make this approach unfeasible. Data regarding the efficacy of reduction of immunosuppression come largely from uncontrolled observational studies in which patients also received other treatment strategies. The majority of early lesions either resolve completely or improve significantly within three to five weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Responses are seen less commonly in other types of PTLD. Reduction of immunosuppression increases the risk of allograft rejection, which may result in death among those with heart, lung, and liver allografts. However, a careful decrease in immunosuppressive therapy based upon the individual's clinical features and type of allograft can result in both a high response rate and a low rate of rejection and allograft loss.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In one study, 42 solid organ transplant recipients with PTLD were treated with reduction of immunosuppression, and 12 also underwent surgical removal of all apparent disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/23\">",
"       23",
"      </a>",
"      ]. Overall, 31 (74 percent) achieved complete remission (CR). Among those treated with reduction of immunosuppression alone, 63 percent had a complete or partial response with a median time to documentation of response of 3.6 weeks. The response was best among patients with early onset disease; in comparison, patients with late onset or extensive disease (as manifested by elevated serum lactate dehydrogenase [LDH], organ dysfunction, and multiorgan involvement) were much less likely to benefit. The response rate was 89 percent in patients with none of these risk factors, compared with none of seven patients with two or three risk factors. Twelve patients developed acute rejection, but only one lost the graft because of rejection. At a median follow-up of almost three years, 55 percent of patients were alive and 50 percent were in CR.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In another study, 148 solid organ transplant recipients with PTLD treated with reduction of immunosuppression had an overall response rate to reduction of immunosuppression of 45 percent (37 percent complete) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/25\">",
"       25",
"      </a>",
"      ]. Approximately 40 percent developed acute rejection and 60 percent required subsequent chemotherapy. Acute rejection did not appear to correlate with the degree of reduction of immunosuppression. Three-year overall survival (OS) was 55 percent. Predictors of worse outcomes included older age (&gt;50 years), B symptoms, bone marrow or liver involvement, weight loss, hepatitis C virus infection, elevated LDH, and dyspnea. Three-year OS was 100 percent in those with no risk factors and 8 percent in patients with two or more risk factors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal reduction of immunosuppression regimen to ensure regression of disease is unknown. Different regimens have been tried based upon the severity of PTLD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/18,26\">",
"     18,26",
"    </a>",
"    ]. The regimen adopted is based upon the severity of the disease in combination with the health risk associated with the possible loss of the allograft. Immunosuppression should be reduced to the lowest tolerated level. Often a reduction to 25 to 50 percent of baseline is used if alternative organ support is available (eg, renal or",
"    <span class=\"nowrap\">",
"     renal/pancreas",
"    </span>",
"    transplant). For heart and lung transplants, a maximum reduction of 50 to 75 percent of baseline is advised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260803914\">",
"    <span class=\"h2\">",
"     Polymorphic PTLD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphic PTLD are polyclonal or monoclonal lymphoid infiltrates that demonstrate evidence of malignant transformation but do not meet all of the criteria for one of the B cell or",
"    <span class=\"nowrap\">",
"     T/NK",
"    </span>",
"    cell lymphomas recognized in immunocompetent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/1\">",
"     1",
"    </a>",
"    ]. For most patients with polymorphic PTLD that expresses CD20, we suggest the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    in addition to reduction of immunosuppression, as tolerated, rather than reduction of immunosuppression alone or this combination with chemotherapy. Patients whose tumors do not express CD20 are not candidates for rituximab therapy and are treated with combination chemotherapy plus reduction of immunosuppression, as tolerated. Surgery may be considered, in addition, for a subset of patients with localized disease.",
"   </p>",
"   <p>",
"    There is a paucity of data regarding the efficacy of different treatment options in this patient population. Most information comes from retrospective or prospective observational studies that combined polymorphic and monomorphic PTLD cases. These are described in the subsequent sections. The preference for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy rather than combined rituximab plus chemotherapy in this patient population places a high value on avoiding toxicities associated with chemotherapy with the understanding that polymorphic PTLD is expected to be less clinically aggressive than monomorphic PTLD. However, the combination of chemotherapy plus rituximab may be occasionally preferred for the treatment of young patients with a good performance status with large volume disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Monomorphic PTLD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monomorphic PTLD are monoclonal lymphoid proliferations that meet the criteria for one of the B cell or",
"    <span class=\"nowrap\">",
"     T/NK",
"    </span>",
"    cell lymphomas recognized in immunocompetent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/1\">",
"     1",
"    </a>",
"    ]. The first step in the management of patients with monomorphic PTLD is reduced immunosuppression as described above. However, only a small minority of cases will respond to reduction of immunosuppression alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/27\">",
"     27",
"    </a>",
"    ]. Patients who are not candidates for reduction of immunosuppression and those who do not have a complete response to this intervention have been treated with chemotherapy, immunotherapy, and occasionally surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/18,23,24,28,29\">",
"     18,23,24,28,29",
"    </a>",
"    ]. There are no randomized trials comparing these treatment options. Instead, data largely come from expert opinion, retrospective analyses and uncontrolled prospective trials. Our approach is similar to that proposed by various consensus guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/18,30,31\">",
"     18,30,31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Reduction in immunosuppression'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with monomorphic PTLD that expresses CD20 (CD20+ PTLD), we suggest the use of reduction of immunosuppression plus the anti-CD20 monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , either alone or in combination with chemotherapy. Single agent rituximab may be considered for patients who have minimal symptoms and for those who are not candidates for initial chemotherapy (eg, poor performance status). All other patients with CD20+ PTLD are offered rituximab plus combination chemotherapy (eg, CHOP), administered concurrently or sequentially. Patients whose tumors do not express CD20 are not candidates for rituximab therapy and are treated with combination chemotherapy plus reduction of immunosuppression alone.",
"   </p>",
"   <p>",
"    Studies that have evaluated these approaches are described in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the ideal treatment of CD20+ PTLD is not known, most clinicians suggest the incorporation of immunotherapy directed against the CD20 antigen. Support for this approach comes from nonrandomized studies of immunotherapy in PTLD and the extrapolation of data from randomized studies and meta-analyses regarding the use of these agents in other conditions. Anti-CD20 monoclonal antibodies (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) have become a key component to the treatment of other CD20 positive non-Hodgkin lymphomas, such as diffuse large B cell lymphoma and follicular lymphoma, based upon a demonstrated survival benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H4#H4\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Rituximab containing regimens'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=see_link&amp;anchor=H19675536#H19675536\">",
"     \"Initial treatment of advanced stage (III/IV) follicular lymphoma\", section on 'Immunotherapy-based treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    may be administered in combination with chemotherapy (eg, concurrently or sequentially) or as a single agent with plans to proceed to chemotherapy if there is inadequate response. The major toxicities of rituximab include infusion reactions (ie, fevers, rigors, and hypotension) and infections related to immunosuppression. Rituximab also imposes a risk of hepatitis B reactivation among patients positive for hepatitis B surface antigen (HBsAg) or antibodies against hepatitis B core antigen (anti-HBc). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H19#H19\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Rituximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link&amp;anchor=H24#H24\">",
"     \"Secondary immune deficiency induced by drugs and biologics\", section on 'Rituximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    will result in complete remissions in approximately 20 percent of patients with PTLD following either solid organ or hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/19,29,32-47\">",
"     19,29,32-47",
"    </a>",
"    ]. When used in combination with chemotherapy, complete remission rates increase to approximately 65 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/46\">",
"     46",
"    </a>",
"    ]. Examples of the efficacy of such treatment include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an international phase II trial, 70 patients with CD20+ PTLD that had not responded to reduction of immunosuppression were treated with single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per week for four weeks) followed by a four-week rest and then four cycles of chemotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (CHOP, administered every 21 days with growth factor support) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/46\">",
"       46",
"      </a>",
"      ]. Patients with progression during rituximab therapy were treated with CHOP. The overall response rate was 90 percent (68 percent complete), with the majority of complete responses occurring after CHOP. Median progression-free and overall survival were 4.0 and 6.6 years, respectively. The main severe toxicities were leucopenia and infection. Treatment-related mortality was 11 percent.",
"     </li>",
"     <li>",
"      Single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per week for four weeks) was employed in a prospective trial involving 43 evaluable patients with previously untreated B cell PTLD not responding to tapering of immunosuppression [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/38\">",
"       38",
"      </a>",
"      ]. The overall response rate was 44 percent, while overall survival was 86 and 67 percent at 80 days and one year, respectively. The only baseline factor predicting response at day 80 was a normal level of serum lactate dehydrogenase (odds ratio 6.9; 95% CI 1.7-28).",
"     </li>",
"     <li>",
"      In a multicenter study of 80 solid organ transplant recipients with PTLD, who were diagnosed between 1998 and 2008, three-year progression-free and overall survival rates were 57 and 62 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/48\">",
"       48",
"      </a>",
"      ]. Those who did or did not receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      as part of their initial treatment (ie, along with reduction of immunosuppression) had three-year overall survival rates of 73 and 33 percent, respectively.",
"     </li>",
"     <li>",
"      In another study, 60 solid organ transplant recipients with PTLD were treated with single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      with an overall response rate of 59 percent (42 percent complete) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/49\">",
"       49",
"      </a>",
"      ]. Half experienced disease progression within six months of completion of rituximab therapy. Median overall survival was 35 months with one and two-year overall survival rates of 73 and 52 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Monitoring of the EBV viral load may predict clinical response of the tumor to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link&amp;anchor=H17288449#H17288449\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\", section on 'Measurement of Epstein-Barr viral load'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with monomorphic PTLD can be treated with chemotherapy used for non-Hodgkin lymphoma, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , CHOP (cyclophosphamide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , prednisone), dose-adjusted ACVBP (doxorubicin, cyclophosphamide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31123?source=see_link\">",
"     vindesine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , prednisone), and other novel therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/24,50-57\">",
"     24,50-57",
"    </a>",
"    ]. Chemotherapy is usually administered in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for patients with CD20+ PTLD. Patients whose tumors do not express CD20 are not candidates for rituximab therapy and are treated with chemotherapy alone. There have been no randomized studies comparing different chemotherapy regimens in PTLD, and a choice is generally made based upon physician experience and side effect profile. Similarly, the ideal timing of chemotherapy with respect to rituximab therapy (ie, concurrent versus sequential) is not known. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Rituximab'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (CHOP) has been used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for the treatment of newly diagnosed CD20+ PTLD and in the treatment of patients who have progressed after initial rituximab therapy. An international phase II trial of rituximab followed by CHOP resulted in an overall response rate of 90 percent (68 percent complete) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/46\">",
"     46",
"    </a>",
"    ]. The main severe toxicities were leukopenia and infection, and treatment-related mortality was 11 percent. Another study reported that CHOP resulted in an overall response rate of 70 percent among patients with refractory or relapsed disease after treatment with rituximab [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data regarding the use of other regimens is mainly limited to small case series. For most patients, we prefer CHOP chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (R-CHOP). Older adults (ie, over age 60 years) or those with cardiac disease may be considered for non-anthracycline containing regimens used to treated diffuse large B cell lymphoma in these populations. Of importance, given the lack of activity of many of these chemotherapy regimens in the central nervous system (CNS), patients with PTLD involving the CNS should be considered for treatment with protocols used for primary central nervous system lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/59-65\">",
"     59-65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H326785256#H326785256\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Older adults'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H14#H14\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Patients with cardiac disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37914?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and prognosis of primary central nervous system lymphoma\", section on 'Initial Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2104674\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with localized disease and those with central nervous system involvement, involved field radiation therapy, alone or in combination, may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/18,66-68\">",
"     18,66-68",
"    </a>",
"    ]. Data regarding efficacy is largely extrapolated from studies of radiation therapy in localized diffuse large B cell lymphoma and in primary central nervous system lymphoma. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=see_link&amp;anchor=H264593724#H264593724\">",
"     \"Initial treatment of limited stage diffuse large B cell lymphoma\", section on 'Is radiation therapy necessary?'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37914?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and prognosis of primary central nervous system lymphoma\", section on 'Is there a role for radiation therapy?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Adoptive immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adoptive immunotherapy uses EBV-specific cytotoxic T lymphocytes (EBV-CTLs) or donor lymphocyte infusion (DLI) in an attempt to kill dividing B cells in EBV-associated PTLD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/69-80\">",
"     69-80",
"    </a>",
"    ]. Most data using this approach come from retrospective series and small observational studies in hematopoietic cell transplantation (HCT) recipients. In this population, prevention of and remission of EBV-induced PTLD have been achieved in this manner in as many as 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/69,73-76,81-83\">",
"     69,73-76,81-83",
"    </a>",
"    ]. The major complication of adoptive immunotherapy is acute and chronic graft-versus-host disease (GVHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/69\">",
"     69",
"    </a>",
"    ]. DLI may produce GVHD, which does not appear to be a problem with EBV-CTLs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a single center retrospective analysis, 49 HCT recipients with biopsy-proven EBV-positive PTLD were treated with unselected DLI (30 patients) or EBV-specific cytotoxic T cell lines (19 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/83\">",
"       83",
"      </a>",
"      ]. The overall response rate was 84 percent, did not differ by treatment modality, and included patients with central nervous system involvement. A clinical response was usually seen within 15 days of infusion, and complete radiologic resolution occurred by six months. At a median follow-up of 80 months, all deaths attributable to PTLD occurred within 4.3 months; the cumulative incidence of EBV-specific mortality at 12 months was 21 to 24 percent for both groups. The cumulative incidences of acute or chronic GVHD attributed to DLI at one year were 14 percent and 14 percent, respectively. No recipient of EBV-specific cytotoxic T cells developed de novo acute or chronic GVHD or a flare of preexisting GVHD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A phase II multicenter clinical trial of adoptive immunotherapy in 33 patients with PTLD who had failed to respond to conventional treatment the overall response rate to partly HLA-matched T cells was 64 and 52 percent at five weeks and six months, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the risk of GVHD and the availability of other treatment modalities, we reserve the use of adoptive immunotherapy for patients with EBV-associated PTLD that remains following initial therapy. The use of EBV-specific CTLs is a highly attractive approach but is not generally available at many centers. With the development of a series of cell lines this treatment approach could become more feasible in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information concerning mortality of patients with PTLD is largely based upon case reports and retrospective studies. Although the prognosis varies with clonality and extent of disease, published series suggest overall survival rates ranging between 25 to 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/87\">",
"     87",
"    </a>",
"    ]. Mortality with monomorphic PTLD has been reported to be as high as 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/88\">",
"     88",
"    </a>",
"    ]. T cell lymphomas have an extremely poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/8,9,89\">",
"     8,9,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While prognostic factors have been identified in patients with PTLD, none has been validated in a prospective fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/90-93\">",
"     90-93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The largest experience relating to prognostic factors with PTLD in renal transplant recipients was reported in a study from the Israel Penn International Transplant Tumor Registry [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/91\">",
"       91",
"      </a>",
"      ]. The clinical features associated with survival were analyzed among 402 patients with PTLD enrolled in this database from the years 1968 to 2000. Increased mortality rates were associated with a diagnosis within six months versus after six months from transplant surgery (64 versus 54 percent), increasing age, multiple versus single sites (73 versus 53 percent), absence of surgery (100 versus 55 percent), and allograft plus other organ involvement versus allograft involvement alone (64 versus 31 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a multivariate analysis of 61 patients, an Eastern Cooperative Oncology Group (ECOG) performance status &ge;2 (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 1",
"      </a>",
"      ) and more than one site of involvement were associated with significantly worse outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/90\">",
"       90",
"      </a>",
"      ]. At a median follow-up of 22 months, median survival for patients with one or two of these factors was 34 months and one month, respectively. The International Prognostic Index, which is useful for determining prognosis in immunocompetent patients with non-Hodgkin lymphoma, was less useful in this setting (",
"      <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H334141054#H334141054\">",
"       \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Prognosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a multicenter study of 80 solid organ transplant recipients with PTLD, who were diagnosed between 1998 and 2008, three-year progression-free and overall survival rates were 57 and 62 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/48\">",
"       48",
"      </a>",
"      ]. Adverse prognostic factors at the time of PTLD diagnosis included CNS involvement, bone marrow involvement, and hypoalbuminemia. Subjects with zero, one, or &ge;2 of these risk factors had three-year overall survival rates of 93, 68, and 11 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of importance, many of these studies included patients diagnosed with PTLD prior to the availability of the anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , which appears to have improved outcomes in CD20+ PTLD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/48,94\">",
"     48,94",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Rituximab'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     RETRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paucity of data exists concerning solid organ retransplantation in patients with a history of PTLD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest cohort study based upon the",
"      <span class=\"nowrap\">",
"       OPTN/UNOS",
"      </span>",
"      database, outcomes were reported among 69 transplant recipients who survived PTLD and underwent retransplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/96\">",
"       96",
"      </a>",
"      ]. The retransplant surgeries included 27 kidney, 22 liver, nine lung, six heart, four intestine, and one pancreas. Average time for the period from PTLD to retransplant, time from transplant to retransplant, and time for patient survival after retransplant were approximately 2.6, 5.7, and 2.1 years, respectively. At follow-up, overall patient and allograft survival was 86 and 74 percent, respectively.",
"     </li>",
"     <li>",
"      One retrospective study reported the outcomes of six patients with kidney retransplantation after cure of EBV-related monoclonal B cell lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?22/50/23338/abstract/95\">",
"       95",
"      </a>",
"      ]. Five of six patients had the PTLD confined to the graft, with all six undergoing allograft nephrectomy in addition to their other treatment. The subsequent time interval from PTLD to retransplant was longer, ranging from 4.1 to 10.6 years. At 24 to 47 months, all patients had functioning grafts without recurrent PTLD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5775658\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Post-transplant lymphoproliferative disorders (PTLD) are serious and potentially fatal complications of chronic immunosuppression in solid organ and hematopoietic cell (HCT) transplant recipients. The pathogenesis of PTLD in most patients relates to the outgrowth of Epstein-Barr virus (EBV)-positive B cell proliferations in the setting of chronic T cell immunosuppression. However, EBV-negative tumors and T cell tumors can also occur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The prevention of PTLD largely relies upon limiting patient exposure to aggressive immunosuppressive regimens, aggressive withdrawal and tapering of agents required for graft acceptance, and anti-viral prophylaxis. Many transplant centers have incorporated EBV monitoring into the routine evaluation of patients at high risk for PTLD and preemptive treatment of PTLD at the time of viral reactivation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      or reduced immunosuppression. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of PTLD has varied significantly according to the type of lymphoproliferative disease present, as well as from institution to institution. Immunosuppression reduction is the cornerstone of therapy.&nbsp;Additional therapies include immunotherapy with the CD20 monoclonal antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , chemotherapy, radiation therapy, or a combination of these. Other treatments, such as adoptive immunotherapy with EBV specific cytotoxic T cells, are generally reserved for persistent disease despite initial therapy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our initial management is largely dependent upon the type of PTLD:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Early lesions &mdash; For most patients with early lesions, we suggest reduction of immunosuppression alone rather than in combination with other therapies (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Other agents are generally reserved for those patients with residual disease despite reduced immunosuppression or for those who cannot tolerate reduction of immunosuppression. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Early lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polymorphic PTLD &mdash; For most patients with polymorphic PTLD that expresses CD20 (CD20+ PTLD), we suggest the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in addition to reduction of immunosuppression, as tolerated, rather than reduction of immunosuppression alone or this combination with chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H260803914\">",
"       'Polymorphic PTLD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monomorphic PTLD &mdash; For patients with monomorphic CD20+ PTLD, we suggest the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , either alone or in combination with chemotherapy in addition to reduction of immunosuppression (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Single agent rituximab may be considered for patients who have minimal symptoms and for those who are not candidates for initial chemotherapy. All other patients with CD20+ PTLD are offered rituximab plus combination chemotherapy, administered concurrently or sequentially. Patients whose tumors do not express CD20 are not candidates for rituximab therapy and are treated with combination chemotherapy plus reduction of immunosuppression. Surgery is reserved for patients with complications such as perforation or obstruction. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Monomorphic PTLD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classical Hodgkin lymphoma-like PTLD &mdash; Classical Hodgkin lymphoma-like PTLD is the least common form of PTLD and there is a paucity of data regarding management. For most patients with classical Hodgkin lymphoma-like PTLD we suggest management with chemotherapy with or without radiation therapy according to protocols used for classical Hodgkin lymphoma (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=see_link\">",
"       \"Overview of the treatment of classical Hodgkin lymphoma in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a paucity of information concerning mortality of patients with PTLD. Although the prognosis varies with clonality and extent of disease, published series suggest overall survival rates ranging between 25 to 35 percent. Mortality with monomorphic PTLD and T cell PTLD are higher. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/2\">",
"      Shapiro R, Scantlebury VP, Jordan ML, et al. FK506 in pediatric kidney transplantation--primary and rescue experience. Pediatr Nephrol 1995; 9 Suppl:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/3\">",
"      Shapiro R, Scantlebury VP, Jordan ML, et al. Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation 1999; 67:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/4\">",
"      McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/5\">",
"      Ellis D, Jaffe R, Green M, et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Transplantation 1999; 68:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/6\">",
"      Holmes RD, Sokol RJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant 2002; 6:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/7\">",
"      Funch DP, Walker AM, Schneider G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5:2894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/8\">",
"      Humar A, H&eacute;bert D, Davies HD, et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 2006; 81:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/9\">",
"      Opelz G, Daniel V, Naujokat C, et al. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol 2007; 8:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/10\">",
"      van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99:4364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/11\">",
"      Worth A, Conyers R, Cohen J, et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematol 2011; 155:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/12\">",
"      Cesaro S, Murrone A, Mengoli C, et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005; 128:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/13\">",
"      Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood 2008; 111:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/14\">",
"      Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007; 110:3507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/15\">",
"      Straathof KC, Savoldo B, Heslop HE, Rooney CM. Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol 2002; 118:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/16\">",
"      European best practice guidelines for renal transplantation. Nephrol Dial Transplant 2002; 17 (Suppl 4):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/17\">",
"      Allen U, H&eacute;bert D, Moore D, et al. Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multi-centre experience. Pediatr Transplant 2001; 5:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/18\">",
"      Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol 2010; 149:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/19\">",
"      EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant 2002; 17 Suppl 4:31.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf (Accessed on July 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/21\">",
"      Jagadeesh D, Woda BA, Draper J, Evens AM. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options Oncol 2012; 13:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/22\">",
"      Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/23\">",
"      Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/24\">",
"      Swinnen LJ, Mullen GM, Carr TJ, et al. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995; 86:3333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/25\">",
"      Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(). Am J Transplant 2011; 11:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/26\">",
"      Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/27\">",
"      Swinnen LJ, LeBlanc M, Grogan TM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 2008; 86:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/28\">",
"      Davis CL, Wood BL, Sabath DE, et al. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998; 66:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/29\">",
"      Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/30\">",
"      The American Society of Transplantation Infectious Diseases Guidelines. Am J Transplant 2009; 9(Suppl 4):S92.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf (Accessed on March 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/32\">",
"      Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000; 96:4055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/33\">",
"      Cook RC, Connors JM, Gascoyne RD, et al. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet 1999; 354:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/34\">",
"      Zilz ND, Olson LJ, McGregor CG. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. J Heart Lung Transplant 2001; 20:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/35\">",
"      Blaes AH, Peterson BA, Bartlett N, et al. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 2005; 104:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/36\">",
"      Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/37\">",
"      Verschuuren EA, Stevens SJ, van Imhoff GW, et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 2002; 73:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/38\">",
"      Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006; 107:3053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/39\">",
"      Garnier JL, Stevenson G, Blanc-Brunat N, et al. Treatment of post-transplant lymphomas with anti-B-cell monoclonal antibodies. Recent Results Cancer Res 2002; 159:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/40\">",
"      Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5:2901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/41\">",
"      Jain AB, Marcos A, Pokharna R, et al. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 2005; 80:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/42\">",
"      Gong JZ, Stenzel TT, Bennett ER, et al. Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases. Am J Surg Pathol 2003; 27:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/43\">",
"      Berney T, Delis S, Kato T, et al. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. Transplantation 2002; 74:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/44\">",
"      Trappe RU, Choquet S, Reinke P, et al. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab. Transplantation 2007; 84:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/45\">",
"      Issa N, Amer H, Dean PG, et al. Posttransplant lymphoproliferative disorder following pancreas transplantation. Am J Transplant 2009; 9:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/46\">",
"      Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/47\">",
"      Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/48\">",
"      Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 28:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/49\">",
"      Choquet S, Oertel S, LeBlond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 2007; 86:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/50\">",
"      Smets F, Vajro P, Cornu G, et al. Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation. Transplantation 2000; 69:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/51\">",
"      Mamzer-Bruneel MF, Lom&eacute; C, Morelon E, et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center. J Clin Oncol 2000; 18:3622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/52\">",
"      Oertel SH, Papp-V&aacute;ry M, Anagnostopoulos I, et al. Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide. Br J Haematol 2003; 123:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/53\">",
"      Gross TG, Bucuvalas JC, Park JR, et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005; 23:6481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/54\">",
"      Fohrer C, Caillard S, Koumarianou A, et al. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. Br J Haematol 2006; 134:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/55\">",
"      Taylor AL, Bowles KM, Callaghan CJ, et al. Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. Transplantation 2006; 82:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/56\">",
"      Taj MM, Messahel B, Mycroft J, et al. Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children. Br J Haematol 2008; 140:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/57\">",
"      Knight JS, Tsodikov A, Cibrik DM, et al. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol 2009; 27:3354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/58\">",
"      Trappe R, Riess H, Babel N, et al. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation 2007; 83:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/59\">",
"      Twombley K, Pokala H, Ardura MI, et al. Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation. Pediatr Transplant 2012; 16:E201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/60\">",
"      Izadi M, Fazel M, Saadat SH, Taheri S. Radiotherapy is the best treatment method in post transplant lymphoproliferative disorders localizing in brain: a review of the literature. Ann Transplant 2011; 16:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/61\">",
"      Lieberman F, Yazbeck V, Raptis A, et al. Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation. J Neurooncol 2012; 107:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/62\">",
"      Bonney DK, Htwe EE, Turner A, et al. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. Pediatr Blood Cancer 2012; 58:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/63\">",
"      Patrick A, Wee A, Hedderman A, et al. High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder. J Neurooncol 2011; 103:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/64\">",
"      Nabors LB, Palmer CA, Julian BA, et al. Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate. Am J Transplant 2009; 9:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/65\">",
"      Cavaliere R, Petroni G, Lopes MB, et al. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer 2010; 116:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/66\">",
"      Koffman BH, Kennedy AS, Heyman M, et al. Use of radiation therapy in posttransplant lymphoproliferative disorder (PTLD) after liver transplantation. Int J Cancer 2000; 90:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/67\">",
"      Hsi ED, Singleton TP, Swinnen L, et al. Mucosa-associated lymphoid tissue-type lymphomas occurring in post-transplantation patients. Am J Surg Pathol 2000; 24:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/68\">",
"      Snanoudj R, Durrbach A, Leblond V, et al. Primary brain lymphomas after kidney transplantation: presentation and outcome. Transplantation 2003; 76:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/69\">",
"      O'Reilly RJ, Small TN, Papadopoulos E, et al. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997; 157:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/70\">",
"      Marshall NA, Howe JG, Formica R, et al. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000; 96:2814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/71\">",
"      Moosmann A, Bigalke I, Tischer J, et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010; 115:2960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/72\">",
"      Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/73\">",
"      Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002; 360:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/74\">",
"      Sun Q, Burton R, Reddy V, Lucas KG. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br J Haematol 2002; 118:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/75\">",
"      Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/76\">",
"      Barker JN, Doubrovina E, Sauter C, et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010; 116:5045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/77\">",
"      Haque T, Taylor C, Wilkie GM, et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 2001; 72:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/78\">",
"      Comoli P, Maccario R, Locatelli F, et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 2005; 5:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/79\">",
"      Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006; 108:2942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/80\">",
"      Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 2012; 9:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/81\">",
"      Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/82\">",
"      Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/83\">",
"      Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012; 119:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/84\">",
"      Melenhorst JJ, Leen AM, Bollard CM, et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 2010; 116:4700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/85\">",
"      Icheva V, Kayser S, Wolff D, et al. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 2013; 31:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/86\">",
"      Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/87\">",
"      Savage P, Waxman J. Post-transplantation lymphoproliferative disease. QJM 1997; 90:497.",
"     </a>",
"    </li>",
"    <li>",
"     Immunosuppression and Lymphoproliferative Disorders, Penn I (Ed), PRO/COM, University of Cincinnati Medical Center, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/89\">",
"      Portell C, Nand S. Single agent lenalidomide induces a response in refractory T-cell posttransplantation lymphoproliferative disorder. Blood 2008; 111:4416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/90\">",
"      Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001; 19:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/91\">",
"      Trofe J, Buell JF, Beebe TM, et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant 2005; 5:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/92\">",
"      Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2005; 23:7574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/93\">",
"      Oton AB, Wang H, Leleu X, et al. Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma 2008; 49:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/94\">",
"      Ghobrial IM, Habermann TM, Ristow KM, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005; 46:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/95\">",
"      Karras A, Thervet E, Le Meur Y, et al. Successful renal retransplantation after post-transplant lymphoproliferative disease. Am J Transplant 2004; 4:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/50/23338/abstract/96\">",
"      Johnson SR, Cherikh WS, Kauffman HM, et al. Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis. Am J Transplant 2006; 6:2743.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7335 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-49D3304717-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_50_23338=[""].join("\n");
var outline_f22_50_23338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5775658\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13166231\">",
"      Tapering immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13166266\">",
"      Antiviral prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H260801294\">",
"      Preemptive treatment of viral reactivation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17288044\">",
"      PRETREATMENT ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H260803824\">",
"      Choice of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Early lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Reduction in immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H260803914\">",
"      Polymorphic PTLD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Monomorphic PTLD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2104674\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Adoptive immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      RETRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5775658\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7335\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7335|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17757\" title=\"table 2\">",
"      Int prognostic index NHL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31738?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18458?source=related_link\">",
"      Induction and maintenance of immunosuppressive therapy in cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/17/18714?source=related_link\">",
"      Initial treatment of advanced stage (III/IV) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=related_link\">",
"      Initial treatment of limited stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12474?source=related_link\">",
"      Maintenance immunosuppression following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28280?source=related_link\">",
"      Malignancy after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=related_link\">",
"      Overview of the treatment of classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=related_link\">",
"      Prevention and treatment of acute graft-versus-host disease: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=related_link\">",
"      Prophylaxis of infections in solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37914?source=related_link\">",
"      Treatment and prognosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35385?source=related_link\">",
"      Treatment of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_50_23339="Classification of gastric bezoars";
var content_f22_50_23339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of gastric bezoars",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Phytobezoar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persimmon (diospyrobezoar)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psyllium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fruit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vegetables",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Trichobezoar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pharmacobezoar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteric coated aspirin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extended release capsules (nifedipine, theophylline)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sucralfate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Styrofoam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fungi (candida)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactobezoar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Furniture polish",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shellac",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_50_23339=[""].join("\n");
var outline_f22_50_23339=null;
var title_f22_50_23340="Predictors response lamivudine";
var content_f22_50_23340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Predictors of response to lamivudine",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"5\">",
"        HBeAg seronconversion according to",
"baseline serum alanine aminotransferase levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"1\" rowspan=\"2\">",
"        Pretreatment ALT level",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Placebo",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Lamivudine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        n",
"       </td>",
"       <td class=\"subtitle3\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle3\">",
"        n",
"       </td>",
"       <td class=\"subtitle3\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &le;1 X",
"ULN",
"       </td>",
"       <td>",
"        0/25",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1/53",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;1 to &le;2",
"X ULN",
"       </td>",
"       <td>",
"        3/59",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        8/114",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;2 to &lt;5 X ULN",
"       </td>",
"       <td>",
"        7/82",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        32/164",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;5 X ULN",
"       </td>",
"       <td>",
"        4/26",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        25/60",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"5\" rowspan=\"1\">",
"        Independent",
"predictors of response to lamivudine&dagger;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Factor",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"3\" rowspan=\"1\">",
"        Odds",
"ratio (95 percent CI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Treatment (lamivudine versus placebo)",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        3.93 (2.21 to",
"7.01)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        HAI score (per 1-unit increase)",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        1.17 (1.10 to",
"1.24)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        ALT level (per 10-unit increase)",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        1.04 (1.02 to",
"1.05)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        HBV-DNA level (per 10-unit increase)",
"       </td>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        0.99 (0.97 to",
"1.00)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ULN: upper limit of normal.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Perillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36:186.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_50_23340=[""].join("\n");
var outline_f22_50_23340=null;
var title_f22_50_23341="Caprini risk assessment model";
var content_f22_50_23341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F83739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F83739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified Caprini risk assessment model for VTE in general surgical patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Risk score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        1 point",
"       </td>",
"       <td class=\"subtitle2\">",
"        2 points",
"       </td>",
"       <td class=\"subtitle2\">",
"        3 points",
"       </td>",
"       <td class=\"subtitle2\">",
"        5 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age 41 to 60 years",
"       </td>",
"       <td>",
"        Age 61 to 74 years",
"       </td>",
"       <td>",
"        Age &ge;75 years",
"       </td>",
"       <td>",
"        Stroke (&lt;1 month)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minor surgery",
"       </td>",
"       <td>",
"        Arthroscopic surgery",
"       </td>",
"       <td>",
"        History of VTE",
"       </td>",
"       <td>",
"        Elective arthroplasty",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BMI &gt;25 kg/m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td>",
"        Major open surgery (&gt;45 minutes)",
"       </td>",
"       <td>",
"        Family history of VTE",
"       </td>",
"       <td>",
"        Hip, pelvis, or leg fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Swollen legs",
"       </td>",
"       <td>",
"        Laparoscopic surgery (&gt;45 minutes)",
"       </td>",
"       <td>",
"        Factor V Leiden",
"       </td>",
"       <td>",
"        Acute spinal cord injury (&lt;1 month)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varicose veins",
"       </td>",
"       <td>",
"        Malignancy",
"       </td>",
"       <td>",
"        Prothrombin 20210A",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy or postpartum",
"       </td>",
"       <td>",
"        Confined to bed (&gt;72 hours)",
"       </td>",
"       <td>",
"        Lupus anticoagulant",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of unexplained or recurrent spontaneous abortion",
"       </td>",
"       <td>",
"        Immobilizing plaster cast",
"       </td>",
"       <td>",
"        Anticardiolipin antibodies",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral contraceptives or hormone replacement",
"       </td>",
"       <td>",
"        Central venous access",
"       </td>",
"       <td>",
"        Elevated serum homocysteine",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis (&lt;1 month)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Heparin-induced thrombocytopenia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serious lung disease, including pneumonia (&lt;1 month)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Other congenital or acquired thrombophilia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal pulmonary function",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute myocardial infarction",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congestive heart failure (&lt;1 month)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of inflammatory bowel disease",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medical patient at bed rest",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Interpretation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Surgical risk category*",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Score",
"       </td>",
"       <td class=\"subtitle2\">",
"        Estimated VTE risk in the absence of pharmacologic or mechanical prophylaxis&nbsp;(percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        Very low (see text for definition)",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        &lt;0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        Low",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        1 to 2",
"       </td>",
"       <td class=\"centered\">",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        Moderate",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        3 to 4",
"       </td>",
"       <td class=\"centered\">",
"        3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        High",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        &ge;5",
"       </td>",
"       <td class=\"centered\">",
"        6.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    * This table is applicable only to general, abdominal-pelvic, bariatric, vascular, and plastic and reconstructive surgery. See text for other types of surgery (eg, cancer surery).",
"    <div class=\"footnotes\">",
"     VTE: venous thromboembolism.",
"    </div>",
"    <div class=\"reference\">",
"     From: Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practical guidelines. Chest 2012; 141:e227S. Reproduced with permission from the American College of Chest Physicians. Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_50_23341=[""].join("\n");
var outline_f22_50_23341=null;
var title_f22_50_23342="Collimaters comp a";
var content_f22_50_23342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schema of collimator and compensators",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 362px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    By passing each beam through an aperture shaped to correspond to the cross-sectional area of the lesion in the beam's bird's eye view, the cross-section of each proton beam is conformed to the corresponding silhouette of the lesion (collimation). By interposing specific materials in the beam's path, energy attenuation is achieved to account for the effects of sloping skin surfaces and tissue non-homogeneities (compensation).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_50_23342=[""].join("\n");
var outline_f22_50_23342=null;
var title_f22_50_23343="BP by post-conceptual age";
var content_f22_50_23343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Blood pressure based on post-conceptual age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 608px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Linear regression of mean systolic (top) and diastolic (bottom) blood pressures by postconceptual age in weeks, with 95% confidence limits (upper and lower dashed lines).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: Macmillan Publishers Ltd: Zubrow AB, Hulman S, Kushner H, Falkner B. Determinants of blood pressure in infants admitted to neonatal intensive care units: a prospective multicenter study. Philadelphia Neonatal Blood Pressure Study Group. J Perinatol 1995; 15:470. Copyright &copy; 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_50_23343=[""].join("\n");
var outline_f22_50_23343=null;
